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ABSTRACT OF THE DISSERTATION
Multiple myeloma (MM) is a debilitating hematologic malignancy of terminally
differentiated plasma cells in the bone marrow (BM). Advances in therapeutic regimens and the
use of autologous stem cell transplantation have significantly improved survival rates and quality
of life in patients. However, the disease remains incurable, with shorter, successive remission
cycles following relapse. To reduce systemic, off-target toxicity and improve quality of life, there
is a need for improved stratification of responding patients. Identification of specific,
noninvasive, imaging biomarkers that correlate to therapeutic efficacy is an attractive strategy
for stratifying responding patients, since the use of positron emission tomography (PET),
computed tomography (CT), and magnetic resonance imaging (MRI) is clinically established.
Here, we have developed a strategy for imaging MM disease pathogenesis and response to
clinically relevant therapeutics by studying the bidirectional interactions between the BM
microenvironment and myeloma cells at the cellular, environmental, and anatomical levels.
Specifically, we have validated imaging markers that identify BM and myeloma-specific
behaviors through three specific aims:
The first aim validated the use of the phenylalanine analog 18F-FDOPA for monitoring
the uptake and efficacy of the DNA alkylating agent melphalan, which is used extensively in
elderly, non-transplant eligible patients and in relapsed, refractory disease. 18F-FDOPA uptake
was significantly reduced in melphalan-treated mice with orthotopic myeloma tumors, and was
concordant with the established 18F-FDG-PET imaging. Immunohistochemistry was used to
validate 18F-FDOPA uptake results. Importantly, expression of LAT1, which is known to mediate
18

F-FDOPA and melphalan uptake, was visibly increased, although this may be a result of

increased tumor vascularity. Our results suggest that 18F-FDOPA-PET can provide
complementary imaging to 18F-FDG-PET for monitoring response to melphalan therapy and
overall LAT1 expression in MM.
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The second aim assessed the specificity and sensitivity of the peptidomimetic nearinfrared fluorophore LLP2A-Cy5 for imaging the expression of the activated conformation of the
VLA-4 integrin on the surface of myeloma cells. LLP2A-Cy5 imaging was also used to study
response to treatment with the proteasome inhibitor bortezomib, which forms the backbone of
several front-line MM therapy strategies. Uptake of LLP2A-Cy5 was significantly reduced in
bortezomib-treated mice bearing intramedullary tumors, indicating a reduction in the expression
of activated VLA-4. These observations are concordant with the known downregulation of
adhesion-mediated drug resistance and VLA-4 by bortezomib. Our results indicate the viability
of using LLP2A-Cy5 near-infrared imaging for sensitive, longitudinal assessment of VLA-4
expression for monitoring bortezomib treatment response.
Finally, the third aim validated the use of preclinical, multi-parametric MRI for studying
changes in the BM in a diffuse infiltrative intramedullary tumor model. Longitudinal imaging of
the BM in the femur and tibia demonstrated significant regional differences in T1-weighted
contrast uptake and parametric T2 that correlated to changes in viable tumor burden following
treatment with bortezomib. Hematoxylin and eosin staining (H&E) was used to validate the MRI
observations. H&E showed complete diffuse infiltration of the BM in untreated animals, while
bortezomib therapy caused the concentration of tumor burden near the epiphyseal plate of the
distal femur and proximal tibia. These observations, in combination with MRI results, establish
the use of preclinical MRI for studying effects of disease progression and therapy response on
the BM in a longitudinal, noninvasive manner.
In summary, these studies established a combination of qualitative observations and
quantitative results in PET, optical, and MRI based strategies. Thus, this project has integrated
a structured, multi-modal approach for assessing changes in tumor burden and monitoring
therapy response at varying granular levels within the myeloma/BM interaction spectrum. Future
studies would adapt this approach into different cell lines and tumor models.
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Chapter 1: Introduction
1.1 Overview
Multiple myeloma (MM) is an incurable, debilitating hematologic malignancy of terminally
differentiated plasma B-cells in the bone marrow (BM). It is the second most common
hematologic malignancy and accounts for 15-20% of all hematologic malignancy-related
mortalities (1,2). In the United States alone, there were over 30,000 estimated new cases and
over 12,000 deaths in 2018 (3). MM median 5-year survival has improved from 34.6% in 2004 to
49.6% in 2013 (4,5). This increase in survival is linked to the improvements in diagnosis and the
availability of autologous stem cell transplantation and combination therapies consisting of
immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics. However,
therapy efficacy in the MM clinical population remains variable, especially at late stages in MM
disease progression. Implementation of personalized stratification strategies is crucial towards
improving patient quality of life and reducing toxicities and costs associated with ineffective
therapies. Noninvasive, whole-body imaging has the potential for improving stratification, with
spatiotemporal localization of therapy response in the MM population. Molecular and structural
imaging of MM burden and its effects on the BM environment can be studied at progressing
levels of granularity, ranging from whole tissue to single cell surface biomarker expression. This
chapter reviews the underlying MM biology, the impact of the BM niche on MM progression,
current and future treatment strategies, and the increasing use of noninvasive imaging for
diagnosis and staging. The section concludes with an overview of the three specific aims
encompassing the efforts towards furthering MM molecular imaging for assessing therapy
response in preclinical MM.

1

1.2

Significance

1.2.1 MM is a plasma cell dyscrasia with spatiotemporal heterogeneity
Multiple myeloma (MM) is a semi-solid plasma cell dyscrasia that develops in bone
marrow (BM) sites, prior to metastasizing to extramedullary lesions. Traditionally, MM is
characterized by abnormal serum levels of non-functional monoclonal immunoglobulin-G (IgG;
M-protein) and the presence of hypercalcemia, renal failures, anemia, and bone fractures
(CRAB) symptoms. MM is the second most common hematologic malignancy after lymphoma
and predominantly affects 65+ year-old adults. Figure 1.1 highlights the epidemiology and the
primary affected populations.

Figure 1.1: Summary of incidence and mortality rates for MM for male and female populations
in the world. Reprinted from (2).
Interestingly, myeloma is a spectrum disease, characterized by a transition from
relatively asymptomatic stages to the symptomatic MM. The asymptomatic stages are primarily
identified by M-protein levels and their rate of progression to symptomatic MM. The first
precursor, monoclonal gammopathy of undetermined significance (MGUS), has approximately a
1 in 100 chance of progression, while the second precursor stage, smoldering myeloma (SM),
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has a 1 in 10 chance. Genome-wide studies have identified several characteristic genetic
mutations associated with each stage, although the drivers for the transition from MGUS to
smoldering myeloma and symptomatic MM are unclear (Figure 1.2) (1,6).

Figure 1.2: Summary of MM progression and genetic diversity. Reprinted from (6).
As noted in Figure 1.2, MM is characterized by clonal heterogeneity and high inter- and
intra-lesion genetic diversity. This diversity is driven partly by the underlying B-cell maturation
process. Immature B-cells are first differentiated from clonal progenitor cells in the
hematopoietic niches in the BM. In pro- and pre- B-cell stages, cells undergo recombination of
genes within the variable heavy and light chain loci. This process is known as VDJ
recombination, due to the involvement of the variable (V), diversity (D), and joining (J) genes,
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and is central to the generation of antigen recognition. Self-reactive B-cells may undergo
receptor editing, wherein secondary rearrangement of light chain variable regions generate
antigen receptors with altered specificity. Failure to complete the maturation phase due to
continued self-reactivity or other causes may also result in apoptosis via clonal deletion.
At this stage, immature B-cells leave the BM and are activated by antigen recognition
and the presence of thymus dependent or independent co-stimulation. Activated B-cells migrate
to the germinal centers of lymph nodes and undergo somatic hypermutation and class switch
recombination to develop specificity to the target antigen (Figure 1.3). Both processes are
mediated by the generation of double strand DNA breaks. These breaks are mostly repaired
locally, but may be joined to breaks at other sites in the genome. These errors result in aberrant
chromosomal translocations, which are considered as a genetic hallmark of myeloma. As a
result of these affinity maturation processes and subsequent maturation to the high affinity
plasma cell stage, B-cells encounter the potential of significant genetic hits that contribute to
subclonal heterogeneity.

Figure 1.3: Summary of B cell maturation pathways and terminally differentiated states. NK,
natural killer; DC, dendritic cell; HSC, hematopoietic stem cell; ELP, early lymphoid progenitor;
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CLP, common lymphoid progenitor; CSR, class switch recombination; MZB, marginal zone B
cells. Reprinted from (7).
Although the etiology of MM is currently unknown, general hallmarks of the disease
include the upregulation of proliferation and cell survival genes, especially in the
RAS/MAPK/ERK pathway, immortalization of plasma cells through abnormal plasma cell
differentiation and resistance to apoptosis via mutations to the P13K/AKT pathways, and the
upregulation of the NF-κB pathway (6). The primary aberrant chromosomal translocations,
which have been recognized primary drivers for nearly 50% of all myeloma-related events, are
the t(4; 14), t(11; 14), t(14; 16), and t(14; 20) (8). Detection of any of these translocations by
cytogenetic assays is correlated to poor prognosis. Additionally, due to the presence of the
transitory, asymptomatic MGUS and SM stages, myeloma plasma cells also undergo additional
mutations and epigenetic changes that contribute to significant spatiotemporal heterogeneity
within individual nascent BM sites.

1.2.2 Interaction between myeloma cells and their BM niche is critical to progression
and survival
The tumor microenvironment has been increasingly linked to a cancer’s aggressiveness
and response to therapy (9,10). These observations are especially true for MM, where
residence in the BM niche protects and promotes the myeloma plasma cell’s immortalization
and transformation. Due to the outsize role of the BM niche on myeloma pathogenesis, it is
important to understand the complex cellular and structural characteristics of the BM, and their
influence on therapeutic response and myeloma disease progression.
The BM is localized within axial and long bones (11). Bones have external cortical bone,
which is composed of dense and osseous bone tissue. Cortical bone is organized into
concentric circles called osteons, with each circular unit made of collagen and calcified
extracellular matrix (ECM). Nerves, lymphatics, and blood vessels run through the middle of the
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osteon in the central canal, with orthogonal, branching vessels to supply surrounding tissue.
Spongy, cancellous bone lines the interior of cortical bone, consisting of lattice-like trabecular
bone. Sites within trabeculae are primarily linked to hematopoietic activity. Figure 1.4
summarizes the bone structure and tissue compartments (12).
1.2.2.1 Adipose Marrow
The BM is composed, primarily, of adipose, yellow marrow and hematopoietic, red
marrow. In humans, the adipose marrow constitutes the diaphysis of the long bones. This
marrow adipose tissue (MAT) can be either constitutive or regulated, and provide endocrine and
paracrine control of skeletal remodeling and hematopoiesis (12,13). The regulated MAT is
concentrated in single adipocyte depots in the proximal femur and vertebrae close to
hematopoietic niches. Regulated MAT expression changes dynamically with external and
physiological stresses, including cold shock, estrogen levels, and age. By contrast, the
constitutive MAT is concentrated in large depots and provide the characteristic yellow marrow
phenotype. Constitutive MAT levels remain relatively stable in response to external drivers, but
increases primarily with age and follows a spatial gradient from distal tibia and caudal vertebrae
to more proximal vertebrae (14).
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Figure 1.4: Summary of BM physiology and cellular components. MSC, mesenchymal stem
cells; HSC, hematopoietic stem cells; CAR cell, CXCL2 abundant reticular cell. Adapted and
reprinted from (12).
The role of MAT in regulating hematopoiesis is controversial in the literature (15).
Generally, there is an inverse correlation between MAT levels and bone mass in both clinical
and preclinical studies (16,17), although regions with high constitutive MAT may be better
protected against bone loss (18). This association is also generally extended to the relationship
between hematopoietic marrow cellularity and MAT deposits. The inverse relationship may be
driven by competition for space within the BM cavity between adipocytes and hematopoietic
cells. This hypothesis is consistent with the observation that implantation of hematopoietic stem
7

cells (HSCs) and adipocyte progenitors result in reductions in overall HSC populations following
irradiation, at least in part due to expansion of the MAT (19). By contrast, other studies have
found a positive impact for MAT on hematopoietic activity in the marrow. In caudal vertebrae, for
instance, secretion of stem cell factor (c-kit) by marrow adipocytes is critical for maintenance of
hematopoietic cells (20). Additionally, adiponectin secretion is linked to improved HSC activation
and recovery following irradiation (21). Finally, regeneration of erythroid progenitors and
granulocytes in leukemia is increased following MAT expansion with peroxisomal proliferator
activated receptor-γ (PPAR-γ) agonists (22). These studies indicate the complexity and
heterogeneity in the observed interactions between marrow adipocytes and hematopoietic cells.
MAT performs an important role in regulating MM through both direct and indirect
mechanisms. Due to fatty acid lipotoxicity, adipocytes have a well-known inhibitory effect on
osteoblast proliferation (23). Additionally, secretion of CXCR2-activating chemokines by marrow
adipocytes may accelerate osteoclast maturation (24). Both of these mechanisms indirectly
assist in myeloma tumor proliferation by enhancing osteolysis and tumor cell escape from the
intramedullary space. MAT also produces several tumor-promoting growth factors, including
interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), and insulin-like growth factor-1 (IGF-1),
which provide significant endocrine signaling leading to cell migration, resistance, and
proliferation pathways (25). Activation of the MAPK/ERK and Akt pathways by TNFα, for
instance, stimulates IL-6 production and autocrine signaling in MM cells in a feedforward loop,
which enhances cell proliferation and survival (26,27). Additionally, fatty acid secretion by
marrow adipocytes provides an energy source and serves potentially as an antigen for inducing
tumor-driving mutations during the MGUS state (27,28).
As with the complex and contradictory relationship exhibited between MAT and
hematopoietic tissue, however, there is also significant evidence of inhibitory behavior by the
MAT on MM. Lipid secretions modulate autophagy signaling, which reduce apoptosis from
unfolded proteins in either positive or inhibitory roles (25). Furthermore, obesity may provide
8

high-energy lipids and signaling that translates to poor prognosis due to increased drug
resistance. However, severely obese or morbidly obese patients in one study (n = 1087) were
found to respond more strongly to melphalan therapy, resulting in improved progression-free
and overall survival rates relative to normal and overweight patients (29). Furthermore,
adipokines, such as adiponectin and leptin, also have an impact on MM cell survival.
Adiponectin is an anti-inflammatory cytokine secreted primarily by adipocytes, but also by
osteoblasts and BM mesenchymal stem cells (MSCs). Adiponectin expression is decreased in
obesity, cardiovascular disease, and myeloma (30). Adiponectin inhibits MM proliferation
through the activation of the protein kinase-A/AMP-activated kinase pathways, resulting in
increased cell death (31). On the other hand, leptin expression increases autophagy response
and suppression of apoptosis in melphalan-treated MM cells. Understanding the role of
individual signaling molecules secreted by adipocytes in the MAT and external adipose tissue
can assist in developing new therapeutic strategies for MM treatment.
1.2.2.2 Hematopoietic Marrow
The hematopoietic (red) marrow primarily constitutes the epiphysis of long bones and
spinal vertebrae and dominates temporally at early ages, before giving way to increasing
constitutive MAT. Hematopoietic niches are predominantly localized within trabeculae in the
perivascular space (32), and are supported by BM stroma, vasculature, and immune cells.
These niches hold HSCs, which provide the regenerating stem cell basis for erythroid, myeloid,
and lymphoid progenitors needed to support red and white blood cell production. Although
HSCs circulate freely in and out of niches, there is evidence suggesting lineage restriction and
localization of progenitors to specialized niches (32,33). For instance, B-cell progenitors are
concentrated in CXCL2-expressing osteoblastic niches that are functionally different from
perivascular niches that primarily maintain HSCs.
Current literature describes the hematopoietic niches as a complex array of MSC,
endothelial cells, and hematopoietic progenitors that drive and regulate hematopoiesis (Figure
9

1.4) (12). The presence of MSCs and factors driving their differentiation into the osteoblast
lineage are linked to HSC expansion and egress from the BM niche (34). Additionally, BM
macrophages, or osteomacs, are critical for erythroid maturation and proliferation, while also
facilitating BM homing and quiescence of HSCs (35-37). Indeed, treatment with granulocyte
colony-stimulating factor was shown to increase differentiation, while reducing osteoblast and
osteomac populations (37). Finally, a population of CXCL2 abundant reticular cells (CAR cells)
promote osteoblastogenesis, perivascular space organization, and establishment of the
microenvironment (38,39).
Micro-vascularization of the BM niches is regulated by the release of angiogenic factors
by BM stromal cells (BMSCs), pericytes, and megakaryocytes located within the endosteam. As
a result, the hematopoietic niches often comprise of a heterogeneous mixture of highly
vascularized and hypoxic regions. The hypoxic regions generally house the quiescent HSCs
and progenitors, while more prolific and differentiating cells are localized within the vascularized
regions (40). The hypoxic microenvironment is maintained by the expression of the hypoxiainducible factor-1α (HIF-1α) and its impact on HSC differentiation. HIF-1α is normally degraded
soon after folding under normoxic conditions by hydroxylating enzymes and the proteasome
complex (41). Under hypoxic conditions, HIF-1α translocates to the nucleus where it
upregulates several glycolytic and pentose phosphate pathway related genes (42). As a result
of this upregulation, oxidative phosphorylation is suppressed, allowing HSCs to tolerate
oxidative stress and maintain quiescence. These conditions, in combination with the immune
tolerance induced by large numbers of immune suppressor cells, result in the BM hematopoietic
niches becoming attractive sites for tumor metastases or generation (43).
1.2.2.3 Bidirectional communication between MM and BM niches
Myeloma cell proliferation and survival is greatly facilitated by the conditions in the BM
niches. The hypoxic environment may play a significant role in the selection of the tumorigenic
genes and maintenance of the cancer cell stem-like behavior for drug resistance. Additionally,
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neovascularization is increased through HIF-1α activation of strong angiogenic proteins,
including the vascular endothelial growth factor-A (VEGF-A) (44). Myeloma cells also generate
a feed-forward loop that support and accelerate tumor cell proliferation. Production of the
receptor activator of NF-κb ligand (RANKL) by osteoblasts and tumor cells and subsequent
stimulation of RANK on pre-osteoblasts results in increases in osteoclast number and activity.
This, in turn, results in increased myeloma tumor cell proliferation through the release of
transforming growth factor-β (TGFβ), insulin-like growth factors (IGFs), and calcium following
bone resorption (Figure 1.5) (45). Additionally, myeloma cells release Dickkopf-1 (DKK-1) in
phenotypically mature MM cells and soluble Frizzled-related proteins (sFRPs) in plasmablastic
states to inhibit BMSC differentiation for osteoblastogenesis (46). These proteins are
antagonists to the Wnt signaling pathway, resulting in the increased production of
osteoprotegerin and RANKL and subsequent osteoclastogenesis (47). Finally, production of
chemokines and cytokines, particularly within in the CXCL12-CXCR4 signaling axis, integrins,
and adhesion molecules by BMSCs and osteoblasts may be linked to improved tumor cell
homing and engraftment within the BM niche.
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Figure 1.5: Summary of the feed-forward loop between tumors and osteolysis, through direct
(solid arrows) and indirect (dotted arrows) means. (MMPs, matrix metalloproteinases; PTHRP,
parathyroid hormone-related protein). MMP2s cleave membrane-bound RANKL (blue balls on
the surface of osteoblasts) or epidermal growth factor-like proteins (red diamonds), resulting in
an increased osteoclastogenesis via a higher ratio of RANKL to osteoprotegerin. Reprinted from
(45).
Interactions with BMSCs provide critical adhesion and drug resistance, through cell
adhesion mediated drug resistance (CAM-DR) pathways. In the presence of myeloma tumor
cells, BMSCs produce several growth and survival proteins, including IL-6, IGF-1, CXCL12 (also
known as stromal cell-derived factor-1 (SDF-1)), VEGF, and RANKL (48). Production of these
cytokines is primarily driven by the overexpression of the bidirectional very-late integrin-4 (VLA4; also known as α4β1) on the surface of the myeloma cells. Expression and activation of VLA-4
is driven by autocrine signaling via myeloma cell-derived macrophage inflammatory protein-1α
(MIP-1α) and VLA-4 binding with vascular cell adhesion molecule-1 (VCAM-1) and fibronectin
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on BMSCs (49). Importantly, VLA-4 is implicated in various myeloma pathogenic behaviors,
including tumor adhesion, survival, proliferation, and drug resistance (50,51).
As described in this overview, myeloma pathogenesis is affected significantly by the BM
niche. Hypoxia, coupled with favorable stromal support and immunosuppressive environment,
provides an attractive, supportive structure for metastatic cancers, including MM. As a result,
the development of stronger understanding of myeloma cell interactions at both intercellular and
environmental levels are critical for improving therapeutic strategies.

1.2.3 MM treatment strategies induce significant changes in BM-resident cells and
affect the BM microenvironment
Therapeutic strategies for MM have advanced significantly in the past two decades,
resulting in substantial improvements in survival rates and patient quality of life. These
pharmaceutical agents target a combination of intracellular pathogenic processes in myeloma
cells and the surrounding environment. This section provides an overview of the literature on
clinical MM therapies and their intracellular and extracellular effects.
Clinical stratification and initial treatment plans are predicated on transplant eligibility and
risk stratification (52). The latter is determined using a combination of factors, including age,
disease stage, and renal function, with further refinement for overall outcome estimation using
the cytogenetic type (53). Based on these outcome estimates, a patient is stratified into
standard, intermediate, and high risk strata. In newly diagnosed transplant-eligible patients,
autologous stem cell transplantation (ASCT) of the hematopoietic marrow is performed following
induction with two- or three-drug combination and high dose melphalan conditioning. By
contrast, elderly, transplant-ineligible patients receive combination therapy followed by singleagent maintenance. The current treatment algorithm for each risk strata and transplant eligibility
is summarized in Figure 1.6.
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Figure 1.6: Treatment strategy for risk strata and transplant eligibility in newly diagnosed MM
patients. (a) Approach in transplant-eligible patients. (B) Approach in elderly, transplantineligible patients. VD, bortezomib-dexamethasone; VCD, bortezomib-cyclophosphamidedexamethasone; VMP, bortezomib-melphalan-predinisone; VRd, bortezomib-lenalidomidedexamethasone. Reprinted from (52).
As noted in Figure 1.6, the majority of combination therapies involve the proteasome
inhibitor bortezomib. Indeed, the approval of bortezomib for clinical use and subsequent
combinations with immunomodulatory drugs (IMiDs) is linked to the improvements in overall
survival seen in the past decade. A decreasing subset of induction combinations use the DNA
alkylator melphalan as the headlining chemotherapeutic, due to relatively poorer progressionfree survival, overall survival, and higher toxicities. Melphalan-centered combination therapies
are instead predominantly used in relapsed and multi-drug refractory scenarios. For each of
these agents, therapeutic efficacy is derived on effecting changes in the targeted myeloma
cellular processes and the supporting BM niches.
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1.2.3.1 Bortezomib
Bortezomib (Velcade, Takeda Pharmaceutical, Inc.) is a small molecule, dipeptide
boronic acid analog. The primary mechanism of action for bortezomib is the reversible binding
of the 26S proteasome subunit, triggering apoptosis through the unfolded protein response.
Specifically, bortezomib has high affinity for the β5 subunit, which confers chymotrypsin-like
functionality. The dipeptide groups form an anti-parallel β sheet conformation via hydrogen
bonding to conserved amino acid residues in the β5 subunit. The boronic acid moiety forms a
reversible stable adduct with the catalytic site, resulting in the complete inhibition of the
chymotryptic subunit and partial inhibition of the tryptic and caspase-like subunits (54).
The downstream mechanism of action for bortezomib is based on several pathways.
Initially, the primary mechanism was thought to be through the NF-κB pathway. NF-κB is an
oncogenic transcription factor that translocates to the nucleus upon proteasomal degradation of
the inhibiting I-κB (55). Prevention of proteasomal degradation would result in NF-κB remaining
in its inactive complex. However, several studies showed that this effect was cell dependent,
since NF-κB was activated through non-proteasomal degradation of I-κB in peripheral blood
mononuclear cells (56). As a result, it is unlikely that the inhibition of the NF-κB pathway is the
main mechanism of action.
Instead, bortezomib induces apoptosis through a combination of intrinsic and extrinsic
pathways, and the activation of endoplasmic reticulum (ER) stress. In the intrinsic pathway, the
apoptosis regulator Bax accumulates in the cytosol and translocates to the mitochondria,
resulting in the release of cytochrome C and subsequent activation of caspase-9 (57). Inhibition
of proteasomal degradation of the p53 tumor suppressor also results in p53-mediated
apoptosis. The extrinsic pathway involves the downstream increases in c-Jun N-terminal kinase
activity and death-inducing receptors Fas and DR5, which enhances caspase-8 activation (58).
Finally, ER stress is induced by the buildup of misfolded proteins, which triggers apoptotic
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unfolded protein response and caspase-2 mediated cell death (59). The pathways and their
components are shown in Figure 1.7.
Bortezomib therapy also significantly affects the surrounding BM niche. As mentioned in
Section 1.2.2.3, MM engages supporting BMSCs, osteoclasts, and osteoblasts through a
vicious feed-forward loop that causes increasing osteolytic activity, neo-angiogenesis, and drug
resistance. Bortezomib promotes osteoclast apoptosis through the inhibition of p38 mitogenactivated protein kinase (MAPK), activator protein-1, and NF-κB pathways (60). Osteoblast
differentiation from osteoblast progenitors and MSCs is also induced through stabilization of βcatenin, and accumulation of β-catenin and the transcription factor Runx2/Cbfa1 in the nucleus
(61). Furthermore, bortezomib reduces adhesion to BMSCs through the inhibition of the MAPK
pathway, which contributes to a reduction in adhesion-mediated drug resistance (62). Finally,
angiogenesis by BMSCs and other endothelial cells is reduced through down-regulation of
VEGF, IL-6, and other angiogenesis-inducing factors (63).
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Figure 1.7: Summary of apoptotic pathways induced by bortezomib-mediated inhibition of the
catalytic 26S proteasome. Reprinted from (55).
The success of bortezomib and bortezomib-driven combination therapies in MM clinical
care has resulted in significant interest in novel, second- and third-generation proteasome
inhibitors. For instance, the second-generation proteasome inhibitor carfilzomib (Krypolis, Onyx
Pharmaceuticals) has recently been approved for use in MM clinical care in bortezomibrefractory disease and frontline treatment (64,65). Carfilzomib is an irreversibly binding
epoxyketone that also inhibits the chymotryptic β5 subunit (66). The development of these
agents is needed to overcome the challenges of off-target toxicity and cell line-dependent
resistance to bortezomib, which is primarily mediated by mutations in the proteasome subunit
β5 gene and increases in proteasomal capacity (67,68).
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1.2.3.2 Immunomodulatory drugs (IMiDs)
BM niches have immunosuppressive environments that provide a favorable area for
myeloma tumors, especially following the expansion of myeloid derived suppressor cells
(MDSCs) and regulatory T (Treg) cells. Both MDSCs and Treg levels are increased in the tumor
microenvironment and in the peripheral blood (69). MDSCs and myeloma cells have a
bidirectional relationship (70). MDSCs induce myeloma tumor growth through suppression of Tcell mediated immunity, while myeloma cells promote MDSC differentiation from healthy
peripheral blood mononuclear cells. Tumor-induced MDSCs may also contribute to tumorassociated osteolysis due to an increased potential to differentiate into mature, functional
osteoclasts relative to non-tumor controls (69).
Tregs are a subset of CD4+ T cells that suppress antigen-presenting cells and effector T
cells through direct binding or release of IL-10 and TGF-β (69). Increases in Treg levels in the
tumor microenvironment and peripheral blood are correlated to poor prognosis. However, the
direct mechanism of myeloma induction of Tregs is not well understood, although in vitro studies
suggest direct induction in an antigen-presenting cell independent way (71). Regardless, the
inhibition of excess immunosuppression by MDSCs, Tregs, and other tumor-related immune
cells is critical for improving outcomes.
In MM clinical care, this strategy is primarily implemented using immunomodulatory
drugs (IMiDs), often in combination with a proteasome inhibitor or melphalan, and a
corticosteroid (e.g., dexamethasone, prednisone). IMiDs currently used for MM are the firstgeneration thalidomide and second-generation lenalidomide (Revlimid, Celgene Corporation)
and pomalidomide (Pomalyst, Celgene Corporation). While the exact mechanism of action is
unclear, IMiDs induce immunostimulation and MM cytotoxicity through several direct and
indirect pathways. Specifically, second-generation IMiDs cause myeloma cell apoptosis through
the up-regulation of the cell cycle arrest with p21waf1, inhibition of NF-κb, and activation of
caspase-8 (72).
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IMiDs also disrupt the interaction between the myeloma cells and their surrounding
microenvironment by downregulating adhesion, neo-angiogenesis, and the release of cytokines
and growth factors (Figure 1.8A) (73). Thalidomide inhibits TNFα, resulting in the
downregulation of cell surface adhesion molecules, including VLA-4, lymphocyte functionassociated antigen-1 on plasma cells, and VCAM-1 and the intercellular adhesion molecule-1
(ICAM-1) on BMSCs (74). Thalidomide and the second-generation IMiDs also inhibit other
inflammatory cytokines to varying degrees, although the contribution of this action towards
curtailing MM activity is uncertain. Finally, IMiDs display anti-angiogenic behavior, by abrogating
VEGF and basic fibroblast growth factor (βFGF) production through interference of PI3K/Akt
pathway in both BMSCs and plasma cells (75,76).
In addition to disruption of the BM-myeloma environment, all IMiDs augment adaptive
and innate immune system response to MM to some extent (Figure 1.8B), although there is
conflicting evidence for mechanisms or the overall in vivo effect. IMiDs, particularly lenalidomide
and pomalidomide, induce co-stimulation of partially activated CD4+ and CD8+ through
increased production of IL-2 and interferon-γ (IFNγ) (77). The production of IL-2 also promotes
natural killer (NK) cell proliferation, and the second-generation IMiDs also enhance antibodydependent cellular cytotoxicity and the natural NK cell cytotoxic function (78). In Tregs,
lenalidomide and pomalidomide reduce expression of the transcription factor FOXP3, and
subsequently the population and function of the Tregs within the overall T cell population (79).
Despite these observed in vitro effects, the degree to which IMiDs affect
immunosuppression, or general immunoparesis, is unknown. In part, this may be due to the use
of the corticosteroid dexamethasone, which functions as an immunosuppressant. As a result,
patients responding to combination therapies containing dexamethasone and an IMiD show a
significant reduction in T and B lymphocytes, and NK cells. Additionally, Treg suppression in
vitro does not fully translate to clinical results, where response to lenalidomide therapy
correlated to a relative increase in the Treg population, relative to normal MM patients (73).
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Furthermore, there is no significant inhibitory effect on the suppressive function of MDSCs by
either bortezomib or lenalidomide, resulting in increased levels of MDSCs in both BM and
peripheral blood of MM patients (80).

Figure 1.8: Summary of (A) microenvironment and (B) immune system effects induced by
IMiDs. APC, antigen-presenting cell; NKT cell, NK cells with T lymphocyte markers and
functionality; ADCC, antibody-dependent cellular cytotoxicity. Adapted and reprinted from (73).
Given the complex, environment dependent efficacy of IMiDs and their safety profiles,
and the importance of modulating and reducing immunoparesis, there is a significant push in
developing novel cancer immunotherapies, vaccines, and adoptive T cell transfer mechanisms.
Work in engineering chimeric antigen receptor T cells, immune checkpoint antibodies, and
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cancer vaccines has shown considerable promise and potential clinical value. However,
discussion of these technologies is beyond the scope of this review.
1.2.3.3 Melphalan
Melphalan (L-phenylalanine mustard) is one of the oldest chemotherapeutic agents still
used to treat MM. Originally approved in 1962, melphalan is used in combination with
bortezomib, corticosteroids, and IMiDs for elderly, transplant-ineligible patients and as a highdose conditioning regimen prior to ASCT. Due to off-target toxicities and relatively poor overall
survival rates compared to bortezomib-based therapies, melphalan-centered combinations are
slowly being phased out in front-line care, although they are used in patients where bortezomibbased treatment is not feasible (52).
Melphalan induces cell death by alkylating DNA non-specifically and creating crosslinked adducts within the DNA. These adducts can result in deletions and strand breaks,
eventually leading to downstream apoptosis through Bax activation and cytochrome c release
(81). Melphalan may also contribute to the disruption of BM myeloma microenvironment by
inhibiting IL-6 production in BMSCs and osteoblasts, thereby reducing MM autocrine signaling
and recruiting inflammatory cells to the BM niche (82,83). Interestingly, melphalan has also
been suggested to provide immunomodulatory effects in the BM microenvironment, by recruiting
CD8+ T cells and reducing Treg and MDSC populations (84).

1.2.4 Summary
MM is a highly clonal disease that is significantly influenced by its tumor
microenvironment. Myeloma cells utilize bidirectional signaling with other cells in the BM milieu,
including immune cells, BMSCs, osteoblasts, and osteoclasts, resulting in increased myeloma
proliferation, survival, and drug resistance. Although current therapeutic regimens effect marked
reductions in adhesion-mediated resistance, immunosuppression, vascularization, and tumor
burden, MM remains an inherently incurable disease. Indeed, following relapse, each therapy
cycle is successively shorter, resulting in increasing resistance to treatment regimens (85).
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Resistance and relapse are driven by clonal evolution and selection of drug resistant cells, and
adhesion-mediated activation of anti-apoptotic pathways (86). As a result, methods for
identifying resistant phenotypes early are necessary for reducing off-target toxicities, improving
patient quality of life, and affecting changes in the treatment strategy for mitigating increases in
tumor burden.

1.3 Noninvasive imaging provides spatiotemporal sampling of MM
staging
1.3.1 Introduction
Due to the inevitable relapse and emergence of refractory disease, it is necessary to
assess response to therapy. As an immunoglobulin secreting disease, the traditional method for
screening therapy response is by quantifying serum M-protein load, and, latterly, free light-chain
content with the serum protein electrophoresis (SPEP) and the free light-chain (FLC) assay,
respectively. Liquid biopsies sampled from BM tissue, typically from long bones or the pelvis,
provide the percentage of plasma cells in the BM. This information, in combination with imaging
data such as changes in number of lesions, BM architecture, and tumor metabolic activity, forms
the basis for monitoring the treatment approach.
The SPEP assay is a mainstay for diagnosis and staging of MM and its asymptomatic
precursor states. Using charged, size-dependent diffusion, SPEP assays identify the most
common serum protein fractions. The presence of monoclonal (M) protein is detected as an
intense band or spike in the γ-globulin fractions (87). Response to therapy is correlated to Mprotein intensity, since M-protein production is linked to tumor burden. However, SPEP has a
high detection limit, requiring more than 500-2000 mg/L in serum protein for analysis (88). In
addition, approximately 15-20% of patients have non-secretory, light-chain, or oligo-secretory
MM, which prevents the detection of intact immunoglobulins in the sera. Finally, due to the slow
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clearance rates of IgG antibodies (biological half-life, ~23 days), SPEP is not sensitive to rapid
changes in tumor burden associated with therapy response (89).
To ameliorate some of these concerns, serum FLC assay is increasingly used in MM
staging. In oligo-secretory and light-chain myeloma, M-protein is at low concentrations with
primarily light chain present in the serum. Serum FLC is more rapidly responsive to changes in
immunoglobulin production and secretion than standard SPEP or urine protein electrophoresis.
However, in approximately 3% of initially diagnosed patients and patients that have received
long-term treatment, there is little to no detectable secretion of intact or light-chain
immunoglobulin (90).
Finally, liquid biopsies sampled at the site of myeloma lesions, typically with noninvasive
imaging guidance, provide changes in total myeloma cells present within the biopsy. However,
biopsies sample regions within a lesion and are hindered by both the inter- and intra-lesion
spatial heterogeneity. Because of the clonal and spatial heterogeneity, whole-body noninvasive
imaging is increasingly used in the diagnosis and staging of MM. Changes in BM tumor
microenvironment translate to visible, quantifiable changes in imaging parameters. Therefore,
this section addresses the major imaging technologies used in monitoring treatment response in
MM.

1.3.2 Applications of PET/CT in assessing therapy response
Positron emission tomography (PET) is the workhorse technology for molecular imaging
and treatment response assessment for clinical cancer care. In particular, [18F]fluorodeoxyglucose (FDG) is the primary contrast agent used for imaging due to its versatility
and applicability for inflammatory diseases. In MM care, FDG-PET is used primarily in staging
prognosis following treatment, but due to a combination of factors, it has limited sensitivity and
specificity in intramedullary disease. To assess the role of FDG-PET and its pitfalls in managing
MM care, it is necessary to understand the mechanism behind contrast generation, FDG uptake
and retention biology, and promising alternate tracers.
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1.3.2.1 Principles of image acquisition
PET is a functional imaging technique that detects and transforms radioactive decay into
an image. The contrast agents used for PET are unstable, proton-rich nuclei that decay to the
immediate lower atomic number, while keeping the mass number constant. There are two
common methods for this decay. The first is via positron emission, where a proton decays to a
neutron, positron (e+), and neutrino (ν) ((1.1). The other method is by electron capture, where
the nucleus captures an orbital electron and converts a proton to a neutron, while releasing xrays or gamma rays ((1.2). The two methods compete with one another, with positron emission
dominant in low atomic number (Z) nuclei and electron capture more likely in higher Z nuclei.
𝑍
𝐴𝑀

→
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𝑍
𝐴−1𝐷
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𝑍
𝐴−1𝐷

+𝜈

(1.1)
(1.2)

The emitted positron has a very short lifetime. Upon encountering an electron, the
positron and electron combine and annihilate, resulting in the generation of two 511 kiloelectronvolt (keV) γ-photons traveling in opposite, collinear directions. This process has several
advantages that are harnessed for PET image generation. The first is that the generated
photons have energies that are an order of magnitude higher than those of diagnostic x-rays,
which reduces risk of attenuation by tissue and enhances external detection. More importantly,
the collinear nature of the emission is detected at opposite ends within a timing window,
resulting in coincidences that provide collimation without the need for physical collimators. As a
result, PET offers highly sensitive imaging that translates to improvements in temporal
resolution and image quality.
However, this coincidence detection is affected by unwanted coincidental sources, which
significantly hamper the signal to noise ratio. These unwanted sources include scattered,
random, and multiple coincidence events. Scattered events are caused by Compton scattering,
where high energy radiation is deflected off nuclei in the radiation path, resulting in loss of
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energy. PET detectors have relatively poor energy resolution, resulting in the acceptance of
different energies, and an incorrect localization of the annihilation event. In random
occurrences, two γ-rays generated from different events are detected within the timing window.
The rate of random coincidences is proportional to the amount of activity and the length of the
timing window. Finally, multiple coincidences occur with the detection of three or more events
within the timing window. The different types of coincidences, both true and accidental are
summarized in Figure 1.9.

Figure 1.9: Summary of the types of possible coincidence events in a PET scanner following
positron annihilation. Reprinted from (91).
The spatial resolution in PET is primarily affected by the positron decay itself, due to the
combination of non-zero positron range and non-collinearity. Non-zero positron range stems
from the distance traveled by the positron before it is annihilated. This energy is dependent on
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the emission energy, which is sampled from an exponential probability distribution bounded
between zero and the maximum endpoint energy. The maximum endpoint energy is dependent
on the difference in atomic mass between the parent and daughter atoms, as well as the excited
state gamma emission. As a result, the positron range limits the maximum attainable spatial
resolution in PET. In addition, the positron often has a non-zero momentum when annihilated,
resulting in the generation of photons that are not traveling in exactly 180o directions. The effect
on spatial resolution by non-collinear photons is driven entirely by the distance between
detectors. As a result, this effect is negligible in small animal PET imaging systems, but
potentially significant in clinical systems.
Because of the use of coincidence events and the absence of physical collimation, PET
possesses higher sensitivity than other imaging technologies. Additionally, scan time is
minimized, leading to improvements in temporal resolution. The main disadvantage of PET is
the poor spatial resolution relative to structural imaging modalities and single photon emission
computed tomography. However, the combination of high sensitivity and temporal resolution
make PET an attractive functional imaging technology for assessing aspects of metabolism and
receptor densities.
1.3.2.2 Mechanisms of FDG contrast generation
FDG is the most commonly used radiotracer for PET imaging and accounts for over 95%
of all radioactivity generated for medical imaging in the United States. It is synthesized by
substituting 18F for the hydroxyl group at the C-2 position in glucose. 18F has a half-life of 109.7
minutes, and is generated with a cyclotron or linear accelerator. As a glucose analog, FDG
probes glucose uptake for glycolysis, which is required for sustenance and upregulated in high
energy tissue, proliferative diseases, and inflammation. Furthermore, glucose is linked to
several metabolic pathways for energy production, nucleotide and amino acid synthesis, and
signaling.
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Glucose uptake is mediated by glucose transporter (GLUT) types 1, 3, or 4. Following
uptake, glucose is phosphorylated and converted into glucose-6-phosphate by hexokinase, at
which point it is either shunted towards glycolysis or nucleotide synthesis through the pentose
phosphate pathway. The primary end product of glycolysis is pyruvate, which is translocated to
the mitochondria where it enters the tricarboxylic acid (TCA) cycle and oxidative
phosphorylation. In non-proliferative cells and normoxic tissue, oxidative phosphorylation is the
dominant pathway following glycolysis for pyruvate, since it produces the most adenosine
triphosphate (ATP) per glucose molecule. Thus, glucose and its products are linked to several
tightly regulated metabolic pathways.
In cancer cells, however, oxidative phosphorylation is minimized, with the majority
converted into lactate, as per the Warburg effect hypothesis (92). This observation implies the
predominance of aerobic glycolysis in cancer cells, which increases glucose accessibility for
generating precursors for fatty acids, nonessential amino acids, and nucleotides, which are
critical for rapid growth and division. Thus, to support proliferative growth, cancer cells have
upregulated GLUT proteins, particularly GLUT1, and hexokinase-2 to mediate glucose uptake
and conversion to glucose-6-phosphate, respectively.
The upregulation of these proteins provide the impetus for FDG contrast generation.
Following uptake, FDG is converted into FDG-6-phosphate, which is unable to progress in later
glycolytic reactions or in the pentose phosphate pathway. Additionally, the hexokinase forward
reaction is generally irreversible, except in select tissues including the liver, where the enzyme
glucose-6-phosphatase convert glucose-6-phosphate back into glucose. Therefore, FDG uptake
is irreversible and correlates to the exogenous glucose metabolism of the cell.
The irreversible nature of FDG uptake and the upregulation of aerobic glycolysis in
tumors makes FDG an attractive contrast agent for imaging active tumors in vivo. Furthermore,
since tumors remain mostly glucose-avid, apoptosis and reductions in tumor burden correlate to
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losses in FDG uptake. As a result, FDG-PET is one of the main imaging technologies for
quantifying treatment response in most cancers.
In MM, however, FDG-PET is not as reliable as in most proliferative cancers. Indeed,
FDG-PET has over 95% sensitivity in detecting extramedullary lesions, but approximately 60%
sensitivity for intramedullary lesions (93). This discrepancy may be due to a combination of
factors. First, intramedullary lesions are composed of largely hypoproliferative cells, in part due
to the influence of the BM microenvironment. More importantly, MM tumors have inconsistent
overexpression of hexokinase-2 and GLUT1, which reduces FDG uptake, even in untreated
tumors. Additionally, uptake of FDG may be compromised by the presence of significant
inflammation, since inflammatory cells are highly glucose-avid, thereby resulting in false
positives. As a result, the most recent International Myeloma Working Group (IMWG) have
deprioritized FDG-PET for diagnostic imaging for MM, although FDG-PET continues to be used
for staging therapy response, especially in extramedullary lesions (94).
1.3.2.3 Alternate tracers
In recent years, there has been an increase in the development and validation of
alternate radiotracers to probe other features of the myeloma pathogenesis. These probes are
specific for overexpressed receptors, transporters, and pathways that are necessary for
myeloma cell function and pathogenesis. The aim of this development is to provide
complementary diagnostic information, and potential links to therapy efficacy since MM
treatment induces significant shifts in BM environmental interaction and expression of critical
pathways.
In addition to glucose uptake, there are several metabolic pathways with clinical
significance in MM. Amino acid transport and fatty acid metabolism are two such pathways. The
synthesis of nonessential amino acids is a vital strategy for all cancers, especially MM due to
the continual overproduction of M-protein. Indeed, the system L amino acid transport protein
family is overexpressed in MM, with high expression of the L-type amino acid transporter-1
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(LAT1) linked to poor clinical prognosis and survival (95). LAT1 is a sodium-independent
obligatory exchange transporter that mediates the transport of aromatic and branched amino
acids. Amino acid uptake from these transporters takes part in intracellular signaling, regulation
of the TCA cycle, protein synthesis, and several other processes. Thus, PET amino acid probes
mostly study the uptake of amino acids and, therefore, expression of the amino acid transporter.
The primary tracers studied for this application are tyrosine, methionine, and phenylalanine
analogs (96). LAT1 imaging for MM using the phenylalaine analog 3,4-dihydroxy-6-[18F]fluoro-Lphenylalanine (18F-FDOPA) and its connection to melphalan therapy efficacy will be explored in
this dissertation.
Fatty acid metabolism is also upregulated in MM. In particular, exogenous acetate
uptake is increased, due to its role in the biosynthesis of nucleotides, amino acids, and cell
membrane components (97). Acetate is ligated with coenzyme-A (CoA) to form Acetyl-CoA, a
highly versatile molecule with several end products. Acetyl-CoA is a precursor for lipid synthesis
through fatty acid synthases, which are overexpressed in myeloma cells. Our lab has previously
demonstrated the utility of
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C-acetate for monitoring response to myeloma therapy (98).

Pharmacological inhibition of fatty acid synthase activity induces significant toxicity in myeloma
cells in vitro and in vivo. In patients, 11C-acetate uptake has been correlated to systemic tumor
burden and provided higher sensitivity for detecting intramedullary diffuse and focal lesions
compared to FDG-PET (99).
In addition to imaging intracellular metabolism, expression of surface markers can be
assessed using PET. For instance, we have demonstrated longitudinal imaging of VLA-4
expression in both intramedullary and extramedullary lesions in vivo, using a 64Cu-labeled
peptidomimetic that is highly specific for the activated conformation of VLA-4 (100). VLA-4
expression is linked to myeloma cell survival, adhesion, and proliferation through bidirectional
signaling with VCAM-1 and fibronectin on the surface of BMSCs. Crucially, VLA-4 is a key
mediator of CAM-DR, and may be used for monitoring therapy response.
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1.3.3 Magnetic resonance imaging is increasingly applied to MM diagnosis and staging
Magnetic resonance imaging (MRI) is a noninvasive structural imaging method that
provides strong soft tissue contrast and resolution. The use of MRI in MM care has increased
significantly over the past decade due to its ability to resolve diffuse and focal intramedullary
lesions. Due to the complimentary potential of multiple endogenous and exogenous contrast
mechanisms, MRI is an attractive technology for enhanced detection and quantitative analysis
of lesion changes following therapy.
1.3.3.1 Overview of MRI contrast mechanisms
MRI signal is generated through changes in the magnetic spins of hydrogen molecules
in a strong magnetic field. Hydrogen spins are oriented in the direction of the axis of the
magnetic field (B0) induced by the scanner. The exposure of the magnetic moment in the field
induces angular momentum and precession along the axis of B0 at the Larmor frequency, which
is dependent on the gyromagnetic ratio and the strength of the magnetic field. Thus, at
equilibrium, the z-directional component of the spin is aligned with B0, while the x- and ydirectional components are incoherent and average to zero.
To perturb this equilibrium, radiofrequency (RF) energy is added to the system using
RF coils. RF pulses cause the magnetic moment to become aligned off-axis. The recovery of
the moment to equilibrium is the primary source of contrast in an MR scan. There are two
primary contrast mechanisms. Longitudinal, spin-lattice, relaxation is driven by the recovery of
the z-directional magnetic moment (Mz). Mz inversion by 180o is followed by recovery towards
the direction of B0. This process follows an exponential curve, with the characteristic relaxation
time given by T1 ((1.3). By contrast, transverse, spin-spin, relaxation is driven by the loss of
coherence in xy-plane. The introduction of a 90o RF pulse induces a non-zero average Mxy
component, which decays back to zero with magnetic fluctuations and transfer of energy
between magnetic moments. The characteristic relaxation time for transverse relaxation is given
by T2 ((1.4).
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𝑀𝑧 (𝑡) = 𝑀0 (1 − exp(−𝑡/𝑇1 ))

(1.3)

𝑀𝑥𝑦 (𝑡) = 𝑀0 exp(−𝑡/𝑇2 )

(1.4)

Localization of the MR signal to specific voxels for spatial characterization of T1 and T2
decay is performed using external electromagnets, which generate a gradient field in all
directions in Cartesian space. Gradient pulses are combined with the RF pulse sequences to
create a spatial distribution of transverse magnetization that is first structured as 2D/3D Fourier
space, and then reconstructed into an MR image by taking the inverse Fourier transform. In
general, most MR images are the magnitude component of the Fourier space. Low- and highfrequency components of the Fourier space provide the underlying contrast and edge maps,
respectively.
The potential library of MRI experiments result in several types of contrast. The primary
types are T1- and T2-weighted contrast. In T1-weighted imaging, the combination of generally
low relaxation time (TR) and echo time (TE) results in the selective enhancement of short T1
regions relative to long T1 regions. Tissue with large macromolecules show efficient transfer of
energy from the hydrogen nuclei to enable spins to transition from the high energy to lower
energy state. As a result, tissue rich with macromolecules, such as adipose tissue, possess
shortest T1, while dilute regions, including water-rich tumors and cysts, have relatively higher
T1. Thus, tumors are typically hypointense in non-contrast enhanced T1-weighted imaging.
Introduction of paramagnetic contrast may be used to generate positive contrast,
through T1 shortening. The most common paramagnetic contrast agents are gadolinium
chelates. Gadolinium facilitates energy transfer for hydrogen nuclei by chemical exchange of
water molecules in the inner coordination shell of the gadolinium molecule (101). Gadolinium
chelates are preferentially taken up in tumor and inflammation regions due to high perfusion and
vascular availability, resulting in hyper-intense signal intensity in the tumor region relative to
surrounding tissue.
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T2-weighted images rely on long TR and TE for the enhancement of relatively high T2
regions, such as inflamed or diseased tissue. T2 dephasing is driven by the molecular
environment with dipole-driven non-uniformities in the magnetic field. Regions with high
macromolecular content have a reduced rate of motion for water molecules, resulting in
increased dipolar interactions and subsequent field inhomogeneities that translate to shorter T2.
By contrast, water-rich regions with dilute concentration of macromolecules have rapid rates of
motion, resulting in brief interactions and a more uniform magnetic environment. As a result,
tumor and cystic tissue appears hyper-intense relative to surrounding tissue.
1.3.3.2 Current applications in MM
Due to its strong soft tissue contrast and spatial resolution, MRI is increasingly used in
MM diagnosis and staging. IMWG recommendations suggest that the detection of one or more
focal lesions is a leading indicator for the onset of symptomatic myeloma (94). The primary MR
methods tested in MM clinical care are non-contrast enhanced T1- and T2-weighted imaging,
diffusion weighted, and dynamic contrast enhancing sequences.
Due to the heterogeneous composition of hematopoietic and adipose marrow in the
adult human vertebrae, T1-weighted and fat-suppressed T2-weighted imaging in a non-tumor
bearing case show finely textured hyper-intense and isointense signal in the vertebrae,
respectively. MM intramedullary lesions display focal lesions, diffuse infiltrations, or variegated
textures that are detectable by T1-weighted and fat-suppressed T2-weighted MRI (Figure 1.10)
(102). Several traditional biomarkers, including osteoclast numbers, VEGF expression, and
plasma cell infiltration, are strongly correlated to the presence of these lesions in T1-weighted
and fat-suppressed, T2-weighted imaging (103,104). T1-weighted MRI especially showed a high
correlation between diffuse infiltration in the vertebrae and poor prognosis.
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Figure 1.10: Representative T1-weighted (left) and fat-suppressed (fs) T2-weighted (right) MRI
of spinal column in a patient with symptomatic MM. White arrow, focal lesion; red arrowhead,
diffuse infiltration. Adapted and reprinted from (102).
Most standard MR protocols in imaging MM minimize the use of gadolinium contrast for
highlighting tumor burden contrast due to the renal toxicity of these chelates. The Food and
Drug Administration (FDA) black box warning on gadolinium states a risk of nephrogenic
systemic fibrosis from gadolinium use in patients with renal insufficiencies. MM patients have a
high possibility of renal failures from the release of calcium and M-protein into blood, which
makes gadolinium use a significant challenge in MM. Thus, there is significant research in the
development of alternate T1 and T2 weighted contrast agents, by utilizing ultra-small
superparamagnetic iron oxide nanoparticles (<5nm) or novel doped iron oxide nanoparticles
(105,106). The design and validation of these contrast agents is an active area of research.
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However, gadolinium contrast is used experimentally in both clinical and preclinical
studies for dynamic contrast enhanced (DCE) MRI. In DCE MRI, an intravenous bolus of
gadolinium is tracked using a high temporal resolution gradient echo sequence within a field of
view. Uptake and retention of the contrast agent is a function of vascular density and perfusion.
Using kinetic modeling and curve statistics, DCE data can be converted into multi-parametric
maps for the peak uptake, influx and washout rates, and total uptake (107). In MM, increases in
peak uptake and influx rate derived from two-compartmental modeling of DCE MR in the pelvis
of treated patients correlated with plasma cell infiltration and vessel density (108).
DCE MR can also be combined with diffusion-weighted imaging (DWI). DWI is
dependent on the differential diffusion rates of macromolecules within a magnetic field to
generate T2-weighted signal at two or more diffusion-sensitizing gradients. The characteristic
time of the exponential decay in signal is the apparent diffusion constant (ADC). Voxel-wise
ADC is dependent on several factors, including cell density and tortuosity. In MM, median ADC
correlated to BM cellularity and vascular density, while showing statistically significant
decreases following therapy (109).
Finally, several small studies have explored the use of voxel-wise magnetic resonance
spectroscopy (MRS) to assess adipose tissue content and the ratio of adipose to hematopoietic
marrow. MRS probes the 1D chemical spin composition of a region or voxel and provides a
snapshot of the composing species in that area. MRS is used extensively in imaging brain
tissue, particularly gliomas, where the presence of glutamate, choline, and other small molecule
species correlate to disease progression and stage. In MM, the BM signal is generally
overwhelmed by water and fatty acids, thus rendering MRS as a blunt tool for assessing
adipose fractions. As discussed in Section 1.2.2.1, there is conflicting evidence on the role of
the adipose marrow in regulating and protecting myeloma cells in the hematopoietic marrow.
However, clinical MRS of spinal and pelvic BM has shown significant increases in lipid fractions
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in responding patients, suggesting an increase in adipose tissue relative to the hematopoietic
marrow (110).
In addition to the technologies presented above, there are several imaging and postprocessing strategies explored in the MM MRI literature. There is a recent explosion in studies
using quantitative texture metrics in combination with non-linear regression models and
machine learning approaches. These studies may improve assessments of therapy response by
harnessing more granular information compared to standard statistics. However, research in
these fields is relatively nascent and requires larger datasets to reduce overfitting and other
errors derived from the larger, inhomogeneous MM patient population.

1.3.4 Near-infrared optical imaging provides high-throughput preclinical functional
imaging
As discussed in Section 1.3.2, functional imaging plays an important role in the
diagnosis, staging, and therapy response monitoring in clinical MM care. The primary modality
is PET, which combines high sensitivity and temporal resolution for assessment of tissue
metabolic activity. For preclinical testing and validation of contrast agents and biomarkers,
however, PET has certain disadvantages. The technology is relatively low throughput, and, due
to the positron-based contrast generation, cannot provide support the use of multiple contrast
agents in parallel. Multiplexed biomarkers can be used to identify the spatial distribution of
corresponding metabolic activities at the tissue and individual cell levels.
One preclinical alternative is to use optical imaging. Optical imaging is low cost and highthroughput. Additionally, due to the availability of multiple wavelengths that can be utilized, it
supports the combination of several imaging probes within the same experiment. Crucially, this
provides a method for multiplexing contrast agents for identifying the spatial localization of
target markers within the tissue and cells.
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Fluorescent optical imaging is primarily hampered by its penetration depth and spatial
resolution. All tissue contain several endogenous chromophores that minimize penetration of
excitation and emission light, primarily due to absorbance, while background autofluorescence
contributes to imaging noise. As a result, near infrared (NIR) fluorophores are used for in vivo
imaging, due to the presence of a local minimum in the absorption of 700-900nm wavelengths
by oxygenated and deoxygenated hemoglobin (Figure 1.11) (111). This enhances penetration
and improves sensitivity.

Figure 1.11: Absorption spectra of common tissue components. Hb, deoxygenated hemoglobin;
HbO2, oxygenated hemoglobin. Reprinted from (111).
In MM preclinical research, there is paucity of exogenous NIR fluorophores that are
targeted to myeloma-specific biomarkers. This is partly due to the limited spatial resolution of
fluorescent imaging methods. Although the optical window affords increased light penetration,
tissue turbidity, presence of large macromolecules, and other chromophores cause scattering.
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As a result, fluorescent images exhibit diffuse signal that is more spatially distributed relative to
its generating region. Several experimental methods and technologies have attempted to
reduce the effect of scattering on image generation, including tomographic acquisition,
structured illumination, and scatter correction using Monte Carlo simulations (112-114).
However, these methods are often application specific. Most early stage MM is intramedullary,
which severely restricts the use of fluorescence since dense bone tissue increases scattering.
Despite the limitations, there is some research in imaging joint inflammation for
osteoarthritis and bone injury applications (115). For instance, use of a NIR bisphosphonate
analog in a bone loss model demonstrated specific uptake of the contrast agent in osteonecrotic
areas, indicating regional specificity for modeling bisphosphonate activity in vivo (116).
Bisphosphonates are also used in MM, often in combination with chemotherapeutics, for
promoting bone regrowth following myeloma-induced bone loss (117). Another study imaged
osteoclast activity with a cathepsin-K specific activatable NIR probe to assess bone degradation
and resorption (118). These studies show promise for bone-specific in vivo imaging for
preclinical MM models. Additionally, exogenous fluorophores can be combined with transfection
models that express luciferase or fluorescent proteins for spatial registration of markers. Optical
imaging of VLA-4 activity in intramedullary, immunocompetent MM is explored in this
dissertation.

1.4

Summary
Multiple studies have shown the dependence of MM tumors on the surrounding BM

microenvironment and the role of the bidirectional signaling for influencing disease
pathogenesis and treatment response. Clinical FDG-PET and MRI are critical for monitoring
therapy response and changing treatment paradigms to minimize toxicities and improve patient
quality of life. Both PET and MRI provide indirect metrics on state of disease, although PET
tracers are designed to assess metabolic activity and receptor densities on the tumor cells. As a
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result, PET imaging correlates to the intra-tumor and tumor-microenvironment interactions,
which respond to and affect the therapy response. In preclinical imaging, NIR optical imaging
can provide PET-like sensitivity and offers parallelized biomarker imaging for identifying whole
tissue expression that can be localized ex vivo.
By contrast, MRI provides a macro view on the BM tissue dynamics and its response to
the MM tumors. Use of DCE and DWI in particular highlight angiogenesis and cell density, while
standard T1- and T2-weighted imaging responds to changes in types of intramedullary lesions
following treatment. MM clinical care typically utilizes multiple factors, including changes in total
uptake and number of lesions in FDG-PET, multi-parametric MRI, and a combination of
cytogenetic, serum, and site-specific biopsied markers, to derive an assessment for diagnostics,
staging, and response to therapy. Despite several advances in treatment strategies and early
identification of non-responders for stratification and personalization of care, MM remains
incurable, with successive relapse cycles lasting progressively shorter. Thus, there is a need for
the development and validation of contrast agents and methods for rapidly imaging changes in
BM structure, intratumoral metabolic activity, and tumor to environment interactions.

1.5

Specific aims and Dissertation outline

1.5.1 Specific aims
Myeloma cells’ interaction with the environment and their intracellular metabolic activity
profiles drive disease progression and therapy efficacy. We have identified the following aims to
probe disease behavior at intracellular, myeloma to BM environmental signaling, and
macroscale BM tissue changes in preclinical intramedullary and extramedullary
immunocompetent models of MM.
Aim 1: To validate LAT1 surface expression imaging using FDOPA-PET and develop FDOPAPET uptake metrics as a surrogate for melphalan efficacy.
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Aim 2: To study uptake of the VLA-4 specific optical probe for identifying VLA-4 expression in
vivo and in response to bortezomib therapy.
Aim 3: To identify preclinical MRI parameters for longitudinal imaging of diffuse intramedullary
tumor burden in response to bortezomib therapy.

1.5.2 Dissertation outline
The current chapter provides an overview of BM and MM biology, therapy strategies and
mechanisms, and current imaging paradigms in MM care.
Imaging of LAT1 surface expression and melphalan therapeutic efficacy is covered in
Chapter 2. 18F-FDOPA-PET uptake in aggressive extramedullary MM was compared to
structural tumor burden and LAT1 expression using T2-weighted MRI and
immunohistochemistry, respectively.
In Chapter 3, in vivo imaging of the activated form of VLA-4 was used to assess
response to proteasome inhibitor therapy using bortezomib. Uptake of the peptidomimetic
optical probe in VLA-4 expressing tumor cells was validated using ex vivo flow cytometry and
planar fluorescent biodistribution.
In Chapter 4, the overall effect on BM tissue and tumor burden was assessed
longitudinally using small animal MRI in diffuse, intramedullary disease following bortezomib
therapy. Tumor burden and changes in adipose tissue distribution and tissue density were
validated using hematoxylin and eosin staining of the femur and tibia BM.
Finally, the general conclusions, limitations, and future work are discussed in Chapter 5.
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Chapter 2: Imaging melphalan therapy response in preclinical
extramedullary myeloma with 18F-FDOPA and 18F-FDG PET
2.1

Overview
In this study, 18F-FDOPA uptake in an extramedullary xenograft myeloma lesion was

studied following melphalan therapy. Melphalan related toxicities and poor efficacy is a primary
reason for the increasing lack of adoption of the chemotherapeutic agent in front-line MM clinical
care. However, it is a key component of post-relapse treatment strategies and in elderly,
transplant ineligible patients that cannot receive bortezomib-based regimens. To identify
responding and non-responding patients, we proposed to use 18F-FDOPA uptake as a surrogate
for melphalan efficacy, since uptake of both melphalan and 18F-FDOPA is mediated by the Ltype amino acid transporter-1. Importantly, LAT1 overexpression is linked to poor prognosis in
myeloma, and it is the primary system L transporter that is upregulated in most cancers.
Our results showed a significant decrease in 18F-FDOPA uptake that was concordant
with the established 18F-FDG uptake. Immunohistochemistry showed a visible change in LAT1
expression, although, interestingly, surface density of LAT1 increased following an early and
aggressive melphalan therapy regimen. This study suggests that 18F-FDOPA-PET/CT can serve
as a complementary method to 18F-FDG-PET/CT for imaging melphalan treatment response.
18

F-FDOPA uptake was linked to LAT1 expression and melphalan response, with longitudinal

imaging suggesting stabilization of LAT1 levels and melphalan tumor cytotoxicity. The material
covered in this chapter is published in the Journal of Nuclear Medicine (1).

2.2

Introduction
One of the main therapies used for treating multiple myeloma (MM) is the small molecule

alkylating agent melphalan (2-4). However, melphalan efficacy is variable in the clinical
population, especially in relapsed and refractory MM. It is also implicated in various toxicities
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including severe mucositis and myelosuppression. Thus, stratification of melphalan-responsive
patients in the MM patient population is critical for reducing therapy-induced toxicities.
The L-type amino acid transporter-1 (LAT1) is a key mediator in the uptake and
intracellular accumulation of melphalan and is correlated to melphalan sensitivity and response
in MM and other cancers (5-7). LAT1 (SLC7A5) is a member of the system L family of
transporters and is primarily expressed in fetal liver, bone marrow, placenta, and testes (8,9). It
is overexpressed in MM and correlated to poor myeloma prognosis and survival (7). LAT1 is a
heterodimer consisting of a light chain (SLC7A5), which provides the amino acid transporter
function, and a glycosylated heavy chain subunit (CD98), which provides trafficking and
membrane localization (10,11). LAT1 is implicated in tumor proliferation pathways, through the
mammalian target of rapamycin and glutamine/glutamate signaling pathways (12).
The glucose analog 2-deoxy-2-[18F]-fluorodeoxyglucose (18F-FDG) is currently used for
positron emission tomography (PET) imaging of myeloma and other cancers for disease staging
and monitoring therapy response. Clinical trials in patients with MM have correlated the
suppression of 18F-FDG uptake to improved event-free survival (13). 18F-FDG-PET/CT is useful
for staging and response monitoring in MM, but the sensitivity for detecting marrow involvement
by MM is variable, particularly with relatively low marrow burden of disease (14). 18F-FDG
uptake can be increased in the setting of inflammation after chemotherapy and in the presence
of exogenous or endogenous marrow stimulation. Thus, there is a need for other PET tracers
with increased sensitivity and specificity for detecting intramedullary myeloma, particularly for
low disease burden. Additionally, 18F-FDG uptake and retention is mediated by glucose
transporter-1 (GLUT1) and hexokinase, which are involved primarily in glycolysis. As a result,
18

F-FDG uptake does not report on LAT1 expression and the melphalan sensitivity of MM

tumors.
In this study, we sought an alternative tracer that directly interrogates the functional
status of LAT1. The amino acid PET tracer 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F51

FDOPA) is structurally related to melphalan and is primarily transported into cells by LAT1 (15).
18

F-FDOPA-PET is mostly used in imaging gliomas and neuroendocrine tumors in cancer

patients (16,17). Because LAT1 mediates the intracellular accumulation of both 18F-FDOPA and
melphalan, we hypothesized that the quantification of 18F-FDOPA uptake in myeloma cells will
correlate with melphalan therapy response. Using an immunocompetent xenograft model of
murine myeloma, we demonstrate that 18F-FDOPA could serve as a complementary imaging
agent to 18F-FDG for MM PET imaging and potentially provide additional stratification of
responders and non-responders to melphalan therapy.

2.3

Materials and Methods

2.3.1 Cell Culture and Reagents
5TGM1-GFP (5TGM1) (originally a kind gift from Dr. G. Mundy, Vanderbilt University,
TN, USA; 5TGM1-GFP cells were obtained from Dr. Katherine N. Weilbaecher, Washington
University, Department of Medicine) were maintained at 106 cells/mL in Iscove’s Modified
Dulbecco Medium supplemented with 10% v/v fetal bovine serum and 1%
penicillin/streptomycin (all from Thermo Fisher Scientific, MA, USA). Melphalan (Sigma Aldrich,
MO, USA) was prepared prior to weekly injections from 5 mg/mL 0.1M HCl EtOH stock. 18FFDG and 18F-FDOPA were produced in compliance with current good manufacturing practices
by the Washington University Cyclotron Facility.

2.3.2 Tumor Model and Melphalan Therapy
All animal studies were conducted according to protocols approved by the Washington
University Animal Studies Committee. C57Bl/6 KaLwRij mice were unilaterally injected
subcutaneously in the lower flank region with 106 5TGM1 cells. All tumor implantation and
imaging procedures were conducted under 1-2% v/v isoflurane/100% O2 anesthesia.
Tumor-bearing mice were separated into two independent studies. The first group
consisted of two independent cohorts of treated (n=7) and untreated (n=6) mice, with melphalan
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therapy beginning at 14-18 days after tumor implantation. Imaging was performed at week 4
(Figure 2.1A). The second group (n=3) consisted of mice treated with melphalan beginning
week 3 after tumor implantation. Imaging was performed weekly immediately prior to the start of
the therapy regimen and continued until week 5 (Figure 2.1B). Melphalan therapy was
administered weekly at 10mg/kg intraperitoneally in saline in each of the studies (18).

Figure 2.1: Timeline for melphalan treated and untreated cohorts. Melphalan was administered
weekly beginning either (A) week 2, with imaging performed on separate, contiguous days at
the end of the study, or (B) week 3 post tumor implantation. Longitudinal imaging with MRI,

18

F-

FDG, and 18F-FDOPA PET/CT was initialized prior to the start of therapy for the week 3 cohort
and continued through to week 5 post tumor implantation.

2.3.3 In vivo Structural and Metabolic Imaging
Prior to PET/CT imaging, tumor structural volume was assessed by calipers and small
animal magnetic resonance imaging (MRI). Mice were placed supine within a birdcage
radiofrequency coil and imaged in 4.7 T (200 MHz) Varian/Agilent small animal scanner (Agilent
Technologies, CA, USA). Respiration and body temperature were maintained at approximately
50 breaths/minute and 37 oC, respectively. Transverse T2-weighted contiguous slices were
collected using a spin echo sequence (repetition time, 1.5s; echo time, 40ms; averages, 2; field
of view, 2.5 x 2.5 x 1.6 cm3; data matrix 128 x 128 x 16). Region of interest analysis was
performed using ImageJ (National Institutes of Health, MD, USA).
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18

F-FDG and 18F-FDOPA-PET/CT were performed on separate, contiguous days to

minimize signal cross-contamination. Prior to radiotracer administration, a whole-body 60kVp
CT was acquired on each mouse. Mice were injected intravenously with 7.4 MBq dosage of the
tracer via the lateral tail vein. 60-minute dynamic scans were collected following injection of the
tracer using Inveon PET/CT or Focus F220 PET imaging systems (all from Siemens Healthcare,
Erlangen, Germany). 18F-FDG-PET/CT was performed after mice were fasted for 6-8 hours with
access to water. To standardize imaging, 18F-FDOPA-PET/CT was performed after 18F-FDGPET/CT. 18F-FDG and 18F-FDOPA-PET/CT images were reconstructed using iterative
reconstruction and displayed using Inveon Research Workplace 4.2 (Siemens Healthcare) in
multi-planar views.

2.3.4 PET Image Analysis
Volumetric tumor and control tissue regions of interest were defined using companion
CT and summed PET. Dynamic time activity curves (TACs) were decay corrected and
converted to standard uptake values (SUV) prior to analysis. The metabolic tumor volume
(MTV) (volume of tumor with SUV > 0.42*SUVMax) (19), total lesion avidity (TLA) (Mean SUV in
the MTV (SUVMean, MTV) * MTV), and total uptake (area under the curve of tracer TAC) were
calculated for 18F-FDOPA. MTV, total lesion glycolysis (TLG) (SUVMean, MTV * MTV), and total
uptake were also measured for 18F-FDG. To minimize single voxel noise in SUVMax
measurements, SUVMax was defined as the mean of the 95% isocontour (20).

2.3.5 Immunohistochemistry
Tumor tissue was excised, flash frozen in optimal cutting temperature compound (Tissue
Tek, CA, USA), and stored at -20 oC. Tyramide amplified immunohistochemistry using Perkin
Elmer TSA-Cy3 kit (PerkinElmer, Inc., MA, USA) was performed as per manufacturer’s
protocol(21). Briefly, sections were fixed in 4% v/v paraformaldehyde/phosphate buffered saline.
Endogenous peroxidase and non-specific binding was blocked with 3% H2O2 and 0.5% TSA
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blocking reagent, respectively. Sections were incubated separately overnight at 4 oC with 1:50
dilutions of rabbit polyclonal anti-SLC7A5 (Proteintech Group, Inc., IL, USA), anti-GLUT1
(Abcam, Cambridge, UK), anti-CD98 (Santa Cruz Biotechnology, Inc., TX, USA), and anti-CD31
(Novus Biologicals, Littleton, CO, USA). The slides were mounted with Vectashield anti-fade
mounting medium with DAPI (Vector Laboratories, Inc., CA, USA) after signal amplification with
1:50 TSA-Cy3. Stained slides were imaged on a Zeiss LSM 880 II Airyscan inverted confocal
fluorescence microscope (Zeiss, Oberkochen, Germany). Slides were sequentially imaged with
DAPI (excitation/emission 405/465 nm), GFP (excitation/emission 488/509 nm), and Cy3
(excitation/emission 561/603 nm) filters. As a negative control, muscle tissue excised from the
contralateral leg was stained and imaged using the described settings.

2.3.6 Statistical Analysis
All statistical analysis was performed using GraphPad Prism 5.0 (GraphPad, CA, USA).
Statistical significance between TACs was determined using 2-way analysis of variance
(ANOVA) with repeated measures, while 1-way ANOVA with Bonferroni multiple comparisons
post-testing and Student’s two-tailed t-test were used for avidity, uptake, and volume
comparisons between tracers, treatment, and tissue types. Lin’s concordance correlation
coefficients between 18F-FDOPA and 18F-FDG parameters were calculated using MATLAB
2014b (Mathworks, Inc., MA, USA).

2.4

Results
C57Bl/KaLwRij mice implanted subcutaneously with 5TGM1 congenic unilateral flank

tumors were evaluated for 18F-FDG and 18F-FDOPA uptake at four weeks post tumor injection
with 60 min dynamic PET/CT. Structural tumor volume was assessed with T2-weighted noncontrast enhanced MRI. There was heterogeneous structural tumor volume reduction from
melphalan therapy within the treatment cohort (9.9 ± 7.7-fold) (Table 2.1; Figure 2.2A-B).
Correspondingly, metabolic volume representing 18F-FDG and 18F-FDOPA uptake decreased in
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treated mice relative to untreated mice (Figure 2.3A-B). Decay-corrected dynamic TACs
derived from the tumor volume of interest for 18F-FDG and 18F-FDOPA showed decreased
overall uptake across imaging time for treated mice (Figure 2.3C-D). Interestingly, treatment did
not affect time to steady state in 18F-FDOPA TACs, suggesting that melphalan therapy did not
impact the overall uptake mechanism and washout kinetics in the tumors.
Table 2.1: Summary of 18F-FDOPA and 18F-FDG measurements

Avidity

Treated (n=7)
(Mean ± SEM)
13.07 ± 5.89

Untreated (n=6)
(Mean ± SEM)
603.9 ± 165.9

Untreated : Treated
(Mean ± SEM)
46.21 ± 24.37

44.92 ± 12.05
22.16 ± 7.67

2329 ± 532.1
636 ± 194.5

51.85 ± 18.27
28.7 ± 13.22

28.81 ± 5.35

416.1 ± 182.5

14.44 ± 6.88
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Figure 2.2: Representative T2-weighted MRI transverse images of (A) untreated, (B) week 2-4
treated, and (C) treated weeks 3-5 post tumor implantation, at the (left) pre-treatment baseline
and weeks (middle) 4 and (right) 5.
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Avidity and uptake of both 18F-FDOPA and 18F-FDG were reduced in the treated tumors.
There was a larger reduction in 18F-FDOPA MTV (28.7 ± 13.2-fold) than 18F-FDG MTV (14.4 ±
6.9-fold), although this difference in MTV reduction did not translate to significant correlation
between MTV and structural tumor volume. Reductions in TLA and TLG were similar in treated
tumors (Figure 2.4A). Overall 18F-FDG SUVmax was higher in both untreated and treated tumors
than 18F-FDOPA SUVmax untreated and treated tumors (Figure 2.4B; Table 2.1). 18F-FDOPA
total uptake and maximal uptake metrics fell within control tissue levels upon melphalan
treatment, as measured relative to bone marrow and muscle, while 18F-FDG uptake remained
significantly higher relative to control tissue within the tumor (Figure 2.4C). These results
suggest that changes in 18F-FDOPA uptake may be more specific to melphalan-mediated
reduction in tumor size than 18F-FDG for this tumor model.

Figure 2.3: Localization of tumor and average time activity profile in treated and untreated
5TGM1 tumor-bearing C57Bl/KaLwRij mice imaged with 18F-FDG and 18F-FDOPA PET/CT.
Representative co-registered PET/CT transverse view of (left) untreated and (right) treated
tumors in dynamic (A) 18F-FDG and (B) 18F-FDOPA imaging. TACs from (C) 18F-FDG and (D)
18

F-FDOPA are displayed (mean ± SEM at each time point), with statistical significance

calculated using the 2-way ANOVA with repeated measures (*** p < 0.001).
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Figure 2.4: Distribution of 18F-FDG and 18F-FDOPA uptake and avidity metrics in treated and
untreated 5TGM1 tumor-bearing C57Bl/KaLwRij mice. Scatter plots with mean and SEM
distributions are displayed for (A) TLA (left) and TLG (right), (B) SUVMax, and (C) total uptake for
18

F-FDOPA (left) and 18F-FDG (right). Statistical significance between treated and untreated

cohorts for TLA and TLG was calculated using the two-tailed Student’s t-test, while 1-way
ANOVA with the Bonferroni multiple comparison post-test was used to assess statistical
significance between groups and tissue for SUVMax and total uptake (* p < 0.05, ** p < 0.01, and
*** p < 0.001).
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F-FDOPA measurements were also assessed against 18F-FDG using Lin’s

18

concordance correlation coefficients. Avidity and MTV in the treated cohort were moderately
concordant, while SUVMax and total tracer uptake demonstrated poor agreement (Table 2.2).
Interestingly, 18F-FDOPA TLA and total uptake were correlated more strongly post therapy to
18

F-FDG, while the concordance of MTV and SUVmax between 18F-FDOPA and 18F-FDG was

relatively unaffected. The lack of concordance between 18F-FDOPA and 18F-FDG in the SUVMax
and total uptake is likely linked to the difference in uptake mechanisms, while moderate
agreement between MTV and avidity indicated similar global effects on metabolism in the
setting of effective therapy.
Table 2.2: Summary of Lin's correlation coefficient relative to 18F-FDG-PET/CT parameters

Avidity
MTV
SUVMax
Total Uptake

Treated (n=7)
Mean (5% - 95% CI)
0.41 (0.04 – 0.68)
0.64 (-0.01 – 0.91)
0.03 (-0.11 – 0.16)
0.21 (-0.02 – 0.42)

Untreated (n=6)
Mean (5% - 95% CI)
0.16 (-0.08 – 0.4)
0.55 (0.01 – 0.84)
0.03 (-0.03 – 0.09)
0.02 (-0.02 – 0.06)

We next performed weekly 18F-FDOPA and 18F-FDG-PET/CT and MRI to study the
effect of therapy on established tumors (Figure 2.1B). T2-weighted MRI indicated minimal
structural tumor volume reduction throughout the therapy regimen (Figure 2.2C). 18F-FDG
uptake was significantly reduced in week 1 of therapy, with a return to pretreatment levels
during week 2 (Figure 2.5A; Figure 2.6A). TLG (1.7 ± 0.4-fold), SUVMax (2.1 ± 0.4-fold), and
total 18F-FDG uptake (2.1 ± 0.4-fold) also increased by week 2 of therapy, suggesting a rebound
of glucose-avid tumor cells (Figure 2.6B-D). By contrast, 18F-FDOPA kinetics were unaffected
by the therapy regimen (Figure 2.5B; Figure 2.6A). There was an increase in TLA (2.4 ± 0.9fold) between the pretreatment baseline and week 1, which remained consistent at week 2 (0.8
± 0.2-fold relative to week 1) (Figure 2.6B). There was no corresponding change in SUVMax or
total 18F-FDOPA uptake (Figure 2.6C-D). These results suggested that treatment of established
tumors with melphalan may result in the stabilization of the structural and metabolic tumor
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volumes. Additionally, the lack of correlation between 18F-FDOPA and 18F-FDG uptake indicated
that acute changes in glucose metabolism are independent of changes in the transport and
intracellular metabolism of the amino acid 18F-FDOPA.

Figure 2.5: Representative maximum intensity projections of longitudinal (A)
18

18

F-FDG and (B)

F-FDOPA-PET/CT at the pretreated baseline and weeks 1 and 2 during melphalan therapy.
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Figure 2.6: Distribution of 18F-FDOPA and 18F-FDG uptake metrics during longitudinal treatment
and imaging. (A) TACs for 18F-FDOPA (left) and 18F-FDG (right), with statistical significance
calculated with 2-way ANOVA with repeated measures and Bonferroni comparisons post-test.
(B) TLA (left) and TLG (right) were calculated for each week, as were (C) SUVMax and (D) total
uptake from 18F-FDOPA and 18F-FDG TACs. Time points (weeks 1 and 2) were relative to pretreatment baseline (week 3 post tumor implantation). Statistical significance for the individual
comparisons was calculated using 1-way ANOVA with Tukey post-hoc test (*p<0.05, **p<0.01,
***p<0.001).
Immunohistochemistry was performed on tissue from both treatment groups to evaluate
changes in LAT1 and GLUT1 transporter expression. Changes in LAT1 expression were
modulated by both tumor size and therapy. Mice in the melphalan-treated established tumor
cohort (week 3 treatment group) had reduced LAT1 (Figure 2.7C top) surface density relative
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to the treatment regimen started week 2 post tumor implantation (week 2 treatment group) and
the untreated tumor (Figure 2.7A-B top). The high LAT1 density in the week 2 treatment group
relative to the untreated tumors could be attributed to the smaller tumor size and increased
tumor vascular density. Indeed, LAT1 and GLUT1 expression was generally concentrated near
blood vessels, as confirmed by CD31 staining (Figure 2.8A-B top). The relative lack of LAT1
signal in the untreated tumor may be linked to the heterogeneous distribution of viable GFPexpressing tumor cells within the tumor mass.

Figure 2.7: Immunohistochemistry of LAT1 (top) and GLUT1 (bottom) expression for (A)
untreated and treated tumors with initialization of melphalan therapy at (B) weeks two and (C)
three post tumor implantation. Expression for each stain was visualized as a maximum intensity
projection (63X magnification; 20µm scale bar) separately and as a composite with GFP (green)
and DAPI nuclear stain (blue).

62

Figure 2.8: Immunohistochemistry of CD31 (top) and CD98 (bottom) for representative (A)
untreated and (B) treated tumors with initialization of melphalan therapy at week 2 post tumor
implantation. Expression for each stain was visualized as a maximum intensity projection (63X
magnification; 20µm scale bar) separately and as a composite with GFP (green) and DAPI
nuclear stain (blue).

2.5

Discussion
18

F-FDOPA is an aromatic amino acid PET tracer that is effective for imaging gliomas

and neuroendocrine tumors (16,17). Dimitrakopoulou-Strauss et al showed that 18F-FDOPA and
18

F-FDG uptake provided complementary detection of metastatic melanoma in pretreated

patients (22). 18F-FDOPA uptake by cancer cells is thought to be primarily mediated by LAT1,
making it a promising candidate for imaging LAT1 activity in vivo. Since melphalan uptake is
also mediated by LAT1, we used 18F-FDOPA-PET as a surrogate reporter of melphalan therapy
efficacy in a preclinical, immunocompetent MM model. We evaluated 18F-FDOPA and 18F-FDG
uptake parameters, including TLA, MTV, and SUVMax in vivo in unilateral subcutaneously
implanted 5TGM1 tumors in C57Bl/KaLwRij mice, which served as a model for extramedullary
myeloma. Importantly, uptake of 18F-FDOPA correlated strongly to LAT1 surface expression and
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showed a significant therapy-induced decrease in SUVMax, lesion avidity, and total uptake
relative to untreated tumor.
Preclinical 18F-FDOPA-PET/CT showed demonstrably different tumor uptake in the
untreated and the two therapy groups. Immunohistochemistry of the week 2 treatment group
suggested that decreasing tumor sizes and increased viable tumor fraction were linked to
increased LAT1 expression (Figure 2.7A-B top). To further validate changes in expression of
LAT1, CD98 staining was performed. It should be noted, however, that CD98 also forms
heterodimers with other amino acid transporters, including members of the LAT family(11).
Additionally, CD98 expression is implicated in increased vascular density (Figure 2.8A-B
bottom) (23). The correlation between vascular density and LAT1 expression is corroborated by
11

C-methionine preclinical PET studies of gliomas and brain tumors (24). 18F-FDOPA metrics

also correlated with melphalan sensitivity, with moderate concordance in MTV to the 18F-FDGPET clinical reference standard (Table 2.2). The reduction in 18F-FDOPA uptake indicated the
sensitivity of 18F-FDOPA-PET/CT to melphalan cytotoxicity.
There was a larger effect on total uptake and SUVMax for 18F-FDG in response to
aggressive melphalan therapy (Figure 2.4B-C). The 5TGM1 cell line is highly glucose avid and
aggressive relative to several other human and murine myeloma cell lines. This avidity, coupled
with minimal GLUT1 surface density differences in untreated and treated tumors, may explain
the differences in overall uptake of 18F-FDG relative to 18F-FDOPA in this tumor model. 18F-FDG
SUVMax and total uptake was also significantly higher in the treated tumor relative to non-tumor
tissue. This effect may be partially explained by the recruitment of glucose avid macrophages
and other immune cells to the tumor by therapy-induced inflammation. Nevertheless, 18F-FDGPET/CT provided accurate identification of overall response, while 18F-FDOPA-PET/CT
highlighted melphalan-sensitive tumor populations and showed a greater reduction in MTV in
the treatment group compared to the untreated tumors than did 18F-FDG.
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The differences in 18F-FDOPA and 18F-FDG uptake induced by the aggressive therapy
regimen may be overstated by several factors, including variable tumor viability, immunologic
response, and the homogeneous expression of LAT1 in the viable tumor volume. To address
these concerns, we performed longitudinal 18F-FDOPA and 18F-FDG-PET/CT on established
tumors treated with melphalan (Figure 2.1B). There was no significant difference in 18F-FDOPA
MTV, SUVMax, or total uptake observed during the imaging period (Figure 2.5B; Figure 2.6).
There was a 2.4-fold increase in TLA between the baseline and first week of therapy, which
remained unchanged at the second week (Figure 2.6B). Indeed, immunohistochemistry showed
that LAT1 expression in this treatment group did not differ qualitatively from the untreated tumor,
which suggests therapy-induced stabilization of LAT1 expression within the tumor environment
(Figure 2.7C). By contrast, 18F-FDG SUVMax and total uptake rebounded to pre-treatment levels
after the first week of therapy, indicating reduction in therapy killing effect by the second week
and stabilized tumor viability (Figure 2.6C-D). These results suggest that functional imaging
with 18F-FDOPA and 18F-FDG PET/CT may be linked to tumor viability and melphalan therapy
response.
Use of indirect metabolic markers such as lesion avidity and radiotracer uptake have
been established in the literature as potential parameters sensitive to changes in cancer
staging. TLA and TLG, while derived from similar SUV data, provided different results from total
uptake, due to the selective volumetric information contained within the MTV. TLA is a crucial
semi-quantitative parameter that may provide a surrogate measurement for viable tumor
fraction. TLG is a more mechanistic measurement that represents the tracer uptake mediated
by the glucose transport proteins and the subsequent intracellular trapping of 18F-FDG following
phosphorylation by hexokinases. While phosphorylated 18F-FDG is unable to enter glycolysis
further downstream, TLG can provide information on the changing GLUT1 mediated metabolism
during disease progression and following therapeutic intervention. Indeed, McDonald et al have
shown that 18F-FDG TLG, MTV, SUVMax, and the number of focal lesions strongly correlated to
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MM stage and progression-free and overall survival rates (25). Similarly, our results highlight the
discordance in the changes in TLA and TLG in response to melphalan therapy in the
established tumors. Therefore, 18F-FDG and 18F-FDOPA may provide an assessment of tumor
response to melphalan during early and late stages, respectively.
This study was a proof of concept investigation into 18F-FDOPA-PET imaging of
myeloma and the correlation between 18F-FDOPA to melphalan therapeutic efficacy in an
extramedullary myeloma tumor model. There are several promising results from this study,
including the correlation between 18F-FDOPA and 18F-FDG uptake with tumor viability and early
response to melphalan therapy, respectively. Imaging in other human and murine myeloma cell
lines and animal models with different LAT1 expression and melphalan sensitivity would provide
additional corroboration for the trends seen within these data. Efflux transporters are
predominantly linked to melphalan resistance in in vitro studies of melphalan-resistant myeloma
cell lines (26). Therefore, determining the expression of efflux transporters at various time-points
during melphalan therapy would also provide important information about treatment-mediated
transient changes in influx and efflux transporters. Finally, further investigation into

18

F-FDOPA

uptake and washout mechanisms with metabolite fate analyses and competitive inhibition of 18FFDOPA intracellular uptake can provide the means for developing strong predictive models of
melphalan sensitivity with 18F-FDOPA-PET/CT.

2.6

Conclusion
This study represents, to date, one of the first investigations linking amino acid-based

imaging in MM to therapy response, via the correlation of 18F-FDOPA-PET/CT to melphalan
sensitivity and LAT1 expression. 18F-FDOPA-PET/CT provided viable and complementary
imaging of MM and melphalan therapy efficacy in this tumor model. Finally, uptake of 18F-FDG
and 18F-FDOPA in established tumors were discordant early after treatment initiation, indicating
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the tracers’ independent mechanisms and their individual applications for assessing response to
different stages of melphalan therapy.

2.7
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Chapter 3: Near-infrared imaging of VLA-4 expression for
monitoring bortezomib efficacy in preclinical MM
3.1

Overview
In this study, the uptake of the near-infrared contrast agent LLP2A-Cy5 was correlated to

bortezomib therapy response in an intramedullary MM tumor model. Bortezomib reduces
myeloma cell adhesion to the bone marrow stroma, via the downregulation of the very-late
antigen-4 (VLA-4) integrin. VLA-4 is a bidirectional heterodimeric integrin receptor that is
overexpressed in its active conformation on myeloma cells and is implicated in several MM
pathogenic pathways. We have previously demonstrated VLA-4 overexpression as a promising
imaging biomarker for monitoring MM disease progression using a high affinity peptidomimetic
ligand, LLP2A, conjugated to a nuclear contrast agent. Here, we proposed to use uptake of the
near-infrared fluorescent analog LLP2A-Cy5 for imaging activated VLA-4 overexpression in
response to bortezomib therapy in syngeneic, intramedullary MM.
Our results showed significant decrease in LLP2A-Cy5 uptake in the tumor-bearing
hematopoietic tissue following bortezomib therapy. Flow cytometry and ex vivo tissue
biodistribution identified reduction in LLP2A-Cy5+ populations across most tissue, indicating the
anti-inflammatory behavior of bortezomib. This study suggests that LLP2A-Cy5 optical imaging
can provide an economical and high-throughput alternative to nuclear imaging for imaging
activated VLA-4 expression and bortezomib therapy response. The material in this chapter is
part of a prepared manuscript submission to the journal Blood.

3.2

Introduction
In multiple myeloma (MM) clinical care, the proteasome inhibitor bortezomib is a key

therapeutic agent in front-line regimens. Bortezomib therapy modulates bone marrow (BM)
remodeling by inhibiting the myeloma cells’ interactions with the BM microenvironment. One of
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the main molecules affected by this interruption is the very-late antigen-4 (VLA-4; α4β1 integrin,
also known as CD49d/CD29). VLA-4 is a bidirectional integrin receptor overexpressed on
myeloma cells in the high affinity activated conformation and is strongly implicated in key
signaling pathways of disease pathogenesis, including cell proliferation, trafficking, and
adhesion-mediated drug resistance (1,2). The activated form of VLA-4 binds to fibronectin and
the vascular cell adhesion marker-1 expressed on the surface of BM stromal cells, resulting in
increased cell adhesion and survival within the BM niche (2,3). Bortezomib inhibits several
oncogenic pathways, including NF-κB and MAPK cascades, resulting in increased osteoclast
apoptosis and the downregulation of several inflammatory and angiogenesic cytokines and
factors (4-6). Bortezomib abrogates BM adhesion by downregulating production of the α4
subunit in the VLA-4 heterodimer (1). Thus, bortezomib efficacy may be linked to VLA-4
expression in myeloma cells.
We have previously demonstrated the affinity of the peptidomimetic ligand LLP2A for the
activated conformation of VLA-4 in preclinical extramedullary and intramedullary MM (7-9). In
particular, VLA-4 overexpression was used to monitor MM disease progression in the BM. To
study in vivo and ex vivo overexpression of VLA-4 in an economical and high-throughput
manner, we developed a near-infrared (NIR) fluorescent imaging agent by conjugating LLP2A to
the NIR cyanine dye Cy5 (9). Melanin, hemoglobin, and other endogenous chromophores have
reduced absorption and autofluorescence in the NIR window (650-900nm), resulting in improved
depth penetration (10). Here, we have demonstrated LLP2A-Cy5 as a surrogate for activated
VLA-4 overexpression in syngeneic, intramedullary MM tumors in an immunocompetent mouse
strain. The correlation between bortezomib treatment and activated VLA-4 expression was also
studied.
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3.3

Materials and Methods

3.3.1 Cell culture and reagents
5TGM1-GFP cells (5TGM1; kind gift from Dr. K. N. Weilbaecher, Washington University,
Department of Medicine) were maintained at 106 cells/mL in Iscove’s Modified Dulbecco
Medium supplemented with 10% v/v fetal bovine serum and 1% penicillin/streptomycin (all from
Thermo Fisher Scientific, MA, USA). Bortezomib (Sigma Aldrich, MO, USA) doses were
prepared prior to each therapy injection. LLP2A-PEG4-Cy5 (LLP2A-Cy5) and scrambled
LLP2A-PEG4-Cy5 (scLLP2A-Cy5) were synthesized as previously described (9).

3.3.2 In vitro LLP2A-Cy5 uptake and specificity
5TGM1 cells were plated on 35mm glass bottom MatTek dishes pre-coated with poly-Dlysine (glass no. 1.5; MatTek Corporation, MA) at 105 cells/cm2, and allowed to attach for 1 h at
37oC. Cells were incubated with 1 µM of the Cy5-labelled probes at 4oC for 15 min, and at 37oC
for 2.5 h to assess cell surface binding specificity and cellular internalization, respectively. 10
µg/L Hoechst 34580 (Invitrogen, CA) was added for the last 15 min of incubation to counterstain
cell nuclei. Fluorescence confocal microscopy was performed on a Nikon A1Rsi confocal
microscope (Nikon Corporation, Tokyo, Japan) with 60X and 100X oil immersion objectives
using excitation-emission at 405-450/40 nm (Hoechst 34580), 488-530/20 nm (GFP), and 640660/20 nm (Cy5).

3.3.3 Saturation binding assay
Selective affinity was determined with fluorescence activated cell sorting (FACS).
1.5x105 5TGM1-GFP cells were incubated with varying concentrations of LLP2A-Cy5, with or
without 100nM BIO5192 (Tocris Bioscience, Bristol, United Kingdom), which was used to
assess nonspecific binding. BIO5192 is a highly specific inhibitor for activated VLA-4 (11).
Samples were analyzed on a Beckman Coulter Gallios flow cytometer and data were analyzed
using FlowJo software (TreeStar, Ashland, OR). Total and nonspecific binding coefficients
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(dissociation constant (Kd) and receptor density (Bmax)) were calculated by fitting mean
fluorescence intensity (MFI) versus LLP2A-Cy5 concentration using Prism 5.0 (GraphPad
Software, Inc., CA).

3.3.4 Tumor model and bortezomib therapy
All animal studies were conducted according to protocols approved by the Washington
University Institutional Animal Care and Use Committee. Mice were anesthetized under 2% v/v
isoflurane/100% O2 prior to tumor implantation. Female 4-8 week old C57Bl/KaLwRij mice were
injected intravenously with 106 5TGM1 cells, via the lateral tail vein.
Tumor-bearing animals were divided into untreated (n=5) and treated (n=3) groups.
Bortezomib therapy was administered intraperitoneally at 1 mg/kg twice a week beginning on
day 14 post tumor implantation (12). Untreated animals received vehicle control on the same
schedule.

3.3.5 In vivo NIR imaging
Prior to imaging, hair was removed by gentle clipping and depilatory cream to improve
light transmission. Mice were imaged before and after 18-24 h after intravenous injection of 100
µL of 25 µM LLP2A-Cy5 in 5% v/v DMSO/H2O using the Optix MX3 time-domain diffuse optical
imaging system (Advanced Research Technologies, Montreal, Canada) as previously described
(13). The images were background subtracted to reduce the effects of autofluorescence.

3.3.6 Statistical analysis
Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad, CA, USA).
One-way analysis of variance (ANOVA) with Sidak multiple comparisons test was used to
assess statistical significance between multiple groups, while the Student’s two-tailed t-test was
used for comparisons between two groups. A p-value less than 0.05 was defined as statistically
significant.
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3.4

Results
The specificity and binding affinity of LLP2A-Cy5 for activated VLA-4 expression on cells

was tested in vitro in 5TGM1 cells. 5TGM1 cells were first incubated with LLP2A-Cy5 at 4oC to
reduce non-specific uptake and binding (Figure 3.1A). Cell surface fluorescence was
significantly reduced when 5TGM1 cells were incubated with the scrambled peptidomimetic
(5.86 ± 2.25-fold) and 100-fold excess unlabeled LLP2A blocking (5.01 ± 2.04-fold) (Figure
3.1B, C; Figure 3.2A). Incubation at 37oC for 2.5 h did not result in an increase in intracellular
uptake, with predominantly cell surface signal (Figure 1D). The binding specificity was further
corroborated using saturation binding, resulting in Kd of 117.7 ± 8.69 nM (Figure 3.2B). Minimal
nonspecific binding (NS, 0.01 ± 0.003) was observed in the presence of BIO5192. These results
indicate that LLP2A-Cy5 is specific to VLA-4 expression.
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Figure 3.1: Representative confocal fluorescent images of LLP2A-Cy5 binding in 5TGM1 cells.
(A) 1 µM LLP2A-Cy5, (B) 1 µM scLLP2A-Cy5, and (C) 1 µM LLP2A-Cy5 in presence of 100 µM
unlabeled LLP2A, were incubated with 5TGM1-GFP cells at 4oC for 15 min. (D) 5TGM1 cells
were incubated with 1 µM LLP2A-Cy5 at 37oC for 2.5 h. A-C, 60X magnification, scale bar, 15
µm; D, 100X magnification, scale bar, 3um. Blue channel, DAPI; Red channel, Cy5.
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Figure 3.2: LLP2A-Cy5 uptake in 5TGM1 cells in vitro. (A) Total uptake in cells at 4oC (15 min
incubation). Integrated density is the product of the region of interest area and mean intensity
value. (B) Saturation binding of LLP2A-Cy5 in 5TGM1 cells. Statistical significance was
assessed using 1-way ANOVA with Tukey multiple comparisons test (***p<0.001).
Next, LLP2A-Cy5 was injected intravenously into end-stage untreated (week 4 post
implantation) and bortezomib-treated (week 6 post implantation) mice to assess VLA-4 activity
in response to bortezomib therapy. Imaging was performed 18-24 h after injection of the
contrast agent. In vivo GFP expression was similar in both groups, although LLP2A-Cy5 signal
was approximately 5-fold higher in the treated mice (Figure 3.3A, B). LLP2A-Cy5 signal in the
treated animals was reduced in the pelvis and lower spine, and was primarily concentrated in
the upper vertebrae and other tissue. In the untreated animals, the spatial distribution of LLP2ACy5 uptake correlated to GFP+ regions, indicating specific uptake within 5TGM1 tumors.
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Figure 3.3: Representative 18-24 h fluorescence signal in C57Bl/KaLwRij mice bearing diffuse,
intramedullary 5TGM1 tumors. (A) Untreated, week 4 post tumor implantation. (B) Bortezomib
treated, week 6 post implantation. (Left) GFP, (Middle) Cy5, (Right) Overlay of GFP and Cy5
signal. Scale bar, 10mm.
Ex vivo fluorescent biodistribution confirmed that maximal LLP2A-Cy5 uptake was seen
in the BM and spleen. There was statistically significant reduction in LLP2A-Cy5 fluorescence in
the end-stage treated BM relative to the untreated tissue (6.34 ± 4.48-fold; Figure 3.4A).
Indeed, tissue-to-muscle ratios for each of the extracted organs, including BM (1.11 ± 0.55)
were within 1.26 ± 0.45, indicating minimal uptake of the contrast agent following bortezomib
therapy. Additionally, GFP signal, which is an indicator for tissue-specific, viable tumor burden,
decreased significantly in both spleen (3.42 ± 2.0-fold) and BM (9.78 ± 6.28-fold) (Figure 3.4B).
These data contradict in vivo fluorescence imaging results, which seemed to suggest an
increase in LLP2A-Cy5 signal following treatment.
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Figure 3.4: Ex vivo fluorescence biodistribution in end-stage treated and untreated mice.
Background subtracted fluorescence intensity in each tissue was normalized by the mean
muscle intensity, and presented as Tissue to Muscle ratios. (A) LLP2A-Cy5 biodistribution. (B)
GFP biodistribution. Statistical significance was assessed using 2-way ANOVA with Sidak
multiple comparisons test (*p<0.05).

Figure 3.5: FACS of treated and untreated BM in the femur and tibia. The cell population is the
percentage of GFP+ and LLP2A-CY5+GFP+ cells within all cells in the BM. Statistical
significance was assessed using the Student's two-tailed t-test within each gated group
(**p<0.01, ns, not significant).
Finally, tumor burden and LLP2A-Cy5+ populations were quantified in both
hematopoietic organs with FACS. There was no significant change in tumor burden in either BM
or spleen following treatment (Figure 3.5). By contrast, the activated VLA-4+ cell population
within the BM was significantly reduced following bortezomib therapy (3.21 ± 1.55-fold).
Consistent with the fluorescence intensity biodistribution, spleen tumor burden was low, and as
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a result, remained relatively similar in the treated group compared to the untreated animals
(1.05 ± 0.96-fold reduction). These data indicate that BM uptake of LLP2A-Cy5 and activated
VLA-4 expression changes following therapy response with bortezomib.

3.5

Discussion
LLP2A-Cy5 is a highly specific peptidomimetic ligand conjugated to a NIR fluorescent

contrast agent (7,9). It is targeted to the activated conformation of the VLA-4 heterodimer, which
is overexpressed on the surface of myeloma cells. Overexpression of VLA-4 is linked to
increased drug resistance in MM, due to its participation in cell adhesion-mediated drug
resistance pathways (2). In hematologic malignancies, studies have shown conflicting effects of
VLA-4 expression on prognosis. In acute myeloid leukemia, for instance, overexpression of
VLA-4 on tumor cells is correlated to better prognosis and low to intermediate disease stage
(14). In MM, there is some evidence that VLA-4 expression is linked to reductions in overall
survival and poor response to therapy (15). To further assess the role of VLA-4 in mediating
therapy response in MM, we studied the uptake of LLP2A-Cy5 in a diffuse, intramedullary MM
model using the immunocompetent C57Bl/KaLwRij strain.
We have previously demonstrated that LLP2A conjugated radiotracers have nanomolar
binding affinities to activated VLA-4 expression on 5TGM1 cells (16). To ascertain the specificity
of the optical LLP2A conjugate, saturation binding and confocal imaging of LLP2A-Cy5
incubation with 5TGM1 cells was performed. Non-specific binding was minimal, as
demonstrated by co-incubation with the VLA-4 inhibitor BIO5192, excess unlabeled LLP2A
blocking, and a scrambled, non-specific version of LLP2A-Cy5. Furthermore, the dissociation
constant (Kd) for LLP2A-Cy5 was in the nanomolar range, and within two orders of magnitude of
the nuclear conjugate. This difference in Kd is likely due to the sensitivity of the PET radiotracer,
since the PET tracer is unaffected by noise driven by the confluence of optical absorption,

79

scattering, and autofluorescence. Nevertheless, these results demonstrated the specificity of the
optical LLP2A conjugate for activated VLA-4 expression on myeloma cells.
Confocal binding specificity experiments were first run at 4oC to minimize non-specific
uptake and pinocytosis. Thus, fluorescence signal was concentrated at the cell surface with little
to no internalization. Interestingly, however, when cells were incubated with LLP2A-Cy5 at
physiologic temperature (37oC) for 2.5 h, cell internalization remained minimal. Fluorescence
signal was predominantly localized at the cell surface. VLA-4 has a longer cell surface exposure
relative to other integrins, which suggests that the fluorophore remains trapped at the cell
surface due to constant integrin recycling (17). This behavior suggests an antagonist
mechanism for LLP2A-Cy5, since ligand-based activation of integrins results in endocytosis and
ligand uptake into the endosomes prior to integrin recycling (18).
Next, LLP2A-Cy5 uptake was used to study VLA-4 expression following bortezomib
therapy. Bortezomib is known to inhibit VLA-4 expression and downstream adhesion-mediated
resistance. As a result, we expected reduction in LLP2A-Cy5 uptake following treatment in our
tumor model. Biodistribution and flow cytometry of the hematopoietic organs corroborated this
expectation, although, interestingly, there was a similar, though not significant, decrease in
LLP2A-Cy5 uptake in other tissue, especially muscle and the clearance organs. Bortezomib has
been shown to have anti-inflammatory properties, with reductions in several inflammatory
cytokines observed in arthritic models (19). Thus, bortezomib-induced reduction in general
inflammation and MM-expressed VLA-4 may result in the overall depression in LLP2A-Cy5
uptake and subsequent rapid clearance from tissue within 24 hrs.
The decrease in LLP2A-Cy5 uptake in the tumor-bearing organs correlated to tumor
burden reduction, as measured by flow cytometry. However, in vivo imaging of LLP2A-Cy5 and
GFP expression contradicted ex vivo data, with an increase in LLP2A-Cy5 signal in the endstage, treated cohort. This increase was statistically insignificant, but it suggests the need for
additional longitudinal experiments. To assess the change in VLA-4 expression noninvasively in
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response to therapy, LLP2A-Cy5 imaging could be performed weekly, prior to treatment. This
imaging strategy would also provide necessary normalization and adequate baseline
comparison for the in vivo fluorescent signal.

3.6

Conclusion
In conclusion, our study has demonstrated the comparable viability of LLP2A-Cy5 in vivo

and in vitro to previously studied nuclear LLP2A tracers. LLP2A-Cy5 showed selective VLA-4
binding in tumor tissue, with minimal nonspecific uptake in vitro. Additionally, we present the
utility of LLP2A-Cy5 for tracking activated VLA-4 expression noninvasively in response to
bortezomib therapy. Future work would include longitudinal observation of LLP2A-Cy5 uptake,
testing in alternate myeloma cell lines with different VLA-4 expression profiles, and modeling
bortezomib sensitivity in VLA-4 negative or knockout cell lines. These studies would improve
understanding of VLA-4-driven stratification of proteasome inhibitor therapy response.
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Chapter 4: Longitudinal MRI of bortezomib-treated diffuse tumor
burden in intramedullary myeloma
4.1

Overview
In this study, magnetic resonance imaging (MRI) was used to perform longitudinal,

noninvasive imaging of the bone marrow (BM) space in a diffuse infiltration model of
intramedullary MM. MRI is well established in clinical MM care, and is used extensively in
diagnosis, staging, and identifying therapy response. However, there is a paucity of preclinical
MRI applications for imaging MM disease progression and therapy response. Preclinical studies
afford significant insight into BM remodeling as a function of pathogenesis and treatment. Here,
we have validated longitudinal, multi-parametric MRI for imaging changes in the BM following
treatment with bortezomib, which is known to induce significant remodeling of the bone and BM
microenvironments. To approximate diffuse infiltrative lesions, the immunocompetent
C57Bl/KaLwRij mouse strain was implanted intravenously with the syngeneic 5TGM1-GFP
cells.
Our results showed that uptake of gadolinium contrast increased in the relapsed, treated
cohort compared to the untreated, tumor-bearing animals. There were also significant regional
differences in T1-weighted normalized signal intensities following bortezomib therapy, which
correlated to spatially heterogeneous tumor viability. Parametric T2 relaxation identified overall
tumor burden within the BM. Histology also indicated a reduction in total tumor burden and cell
density following therapy, which was in line with MRI observations. This study highlighted
potential preclinical MR markers for assessing viable tumor burden and BM permeability
following therapy, and demonstrated the application of longitudinal, noninvasive imaging in an
immunocompetent, intramedullary setting. The material covered in this chapter has been
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submitted to NMR in Biomedicine, under the title, “Longitudinal preclinical magnetic resonance
imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy.”

4.2

Introduction
Multiple myeloma (MM) is a cancer of terminally differentiated plasma B-cells in the bone

marrow (BM) that accounts for approximately 15% of all mortalities associated with hematologic
malignancies (1,2). Despite recent improvements in MM treatment, the efficacy of MM
therapeutic strategies is still variable, especially at the late stages of cancer progression (3).
Changes in therapy efficacy are influenced, in part, by the interactions of myeloma cells with the
BM microenvironment. As a result, imaging strategies to noninvasively assess changes in the
BM microenvironment can provide valuable information for treatment stratification.
In MM, clinical magnetic resonance imaging (MRI) is used extensively to delineate
lesions and stage disease progression following treatment (4). Traditional biological markers,
including bone remodeling and angiogenesis-related factors and plasma cell infiltration, are
correlated to the presence of diffuse, variegated, and focal lesions in T1-weighted, non-contrast
enhanced and fat-suppressed, T2-weighted MRI (5,6). In particular, T1-weighted MRI revealed
a high correlation between diffuse infiltration and poor prognosis (5). Diffusion weighted imaging
of MM patients has also identified significant differences in median apparent diffusion
coefficients between responders and non-responders to systemic treatment (7). Kinetic
modeling of vascular transport with T1-weighted, dynamic contrast-enhanced (CE) imaging
identified increases in BM angiogenesis and vascular bed density, which may correspond to the
transition to malignant states of MM (8). Finally, magnetic resonance spectroscopy of spinal and
pelvic BM showed a statistically significant increase in lipid fractions in patients responding to
therapy, indicating a reduction in the ratio of hematopoietic marrow to adipose tissue (9). These
clinical studies demonstrate that MRI is as an attractive option for noninvasively studying
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relative changes in the BM microenvironment during disease progression and for monitoring
therapy response.
While the role of MRI is well established in the clinic, studies demonstrating the potential
of preclinical MRI in MM are scarce. Due to its excellent soft-tissue contrast and resolution, MRI
provides a preclinical platform for studying the BM microenvironment in a noninvasive,
longitudinal manner. Here, we demonstrate the use of multi-parametric MRI for longitudinal
imaging of the viable tumor burden in the BM in a syngeneic immunocompetent model of
intramedullary diffuse MM. Treatment with a proteasome inhibitor, bortezomib, was performed,
due to its relevance in MM clinical care at all stages and its effect on BM remodeling (10).
Effective changes in MR markers were correlated with histology for validation.

4.3

Materials and Methods

4.3.1 Cell culture and reagents
5TGM1-GFP cells (5TGM1; kind gift from Dr. K. N. Weilbaecher, Washington University,
Department of Medicine) were maintained at 106 cells/mL in Iscove’s Modified Dulbecco
Medium supplemented with 10% v/v fetal bovine serum and 1% penicillin/streptomycin (all from
Thermo Fisher Scientific, MA, USA). Bortezomib (Sigma Aldrich, MO, USA) doses were
prepared prior to each therapy injection.

4.3.2 Tumor model and bortezomib therapy
All animal studies were conducted according to protocols approved by the Washington
University Institutional Animal Care and Use Committee. Mice were anesthetized under 2% v/v
isoflurane/100% O2 prior to tumor implantation. Female 4-8 week old C57Bl/KaLwRij mice were
injected intravenously with 106 5TGM1 cells, via the lateral tail vein.
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Figure 4.1: Study design, imaging, and therapy timeline. Untreated tumor-bearing (N = 5)
5TGM1/KaLwRij were imaged weekly with non-CE T2 parametric mapping and 3D CE T1weighted MR weekly beginning two weeks post 5TGM1 tumor implantation. The bortezomib
treatment cohort (N = 9) was similarly implanted with 5TGM1 tumors and injected with
bortezomib via intraperitoneal injection at 1 mg/kg twice a week, beginning two weeks post
tumor implantation. On imaging days (e.g., day 14, 21, 28), therapy and vehicle injections were
performed immediately following imaging. As with the untreated tumor-bearing cohort, each
mouse was imaged weekly with non-CE T2 parametric mapping and a 3D CE T1-weighted
pulse sequence.
Tumor-bearing mice were separated into randomly assigned untreated (n=5) and
bortezomib-treated (n=9) independent cohorts (Figure 4.1). Bortezomib therapy was
administered intraperitoneally at 1 mg/kg twice a week beginning on day 14 post tumor
implantation(11). Untreated animals received the vehicle control on the same schedule. Nontumor bearing animals (n=4) were imaged once.

4.3.3 Preclinical MRI
Preclinical 1H MRI experiments were performed on a 4.7-T Agilent/Varian (Santa Clara,
CA, USA) DirectDrive MRI scanner employing a horizontal Oxford Instruments (Abington,
Oxfordshire, UK) magnet with 40-cm clear bore diameter and an actively shielded Resonance
Research Inc. (Billerica, MA) gradient/shim coil assembly of 11.5-cm bore diameter driven by
Oy International Electric Company (IEC; Helsinki, Finland) model A-240 amplifiers (~70
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gauss/cm is achievable with a rise time of ~120 µs). All imaging experiments were conducted
under 1% v/v isoflurane/100% O2 anesthesia. Mice were placed prone, with the hind leg
immobilized within a tuned circular radiofrequency surface coil. The hind leg was used to image
changes in large BM sites with minimal motion artifacts. Body temperature was maintained with
an external air heater. Planning and localization of femur and tibia regions of interest (ROIs)
were performed using sagittal (field of view (FOV) 2.5x2.5x0.5 cm3) and transverse (FOV
1.5x1.5x1 cm3) T1-weighted gradient echo sequences (flip angle 20o, repetition time (TR)
100ms, echo time (TE) 5 ms). Following field shimming, T2 parametric maps were collected
using multi-slice, multiple spin echo (FOV 2x2x0.3 cm3, TR 2s, 7.1 ms ≤ TE ≤ 113.5 ms, 16
echoes, 0.156x0.156x1 mm3 voxel dimensions, 128x128x3 matrix dimensions, 1 average). Mice
were then injected intraperitoneally with 12 µmol MultiHance (Bracco Diagnostics, NJ, USA). To
allow the contrast agent to accumulate and approach steady state, CE T1-weighted gradient
echo 3D images were collected 8-10 minutes following injection of the agent (FOV 2x1x1 cm3,
flip angle 20o, TR 25 ms, TE 4.2 ms, 0.78x0.78x0.78 mm3 voxel dimensions, 128x256x128
matrix dimensions, 4 averages).

4.3.4 Bone histology and imaging
Following euthanasia, femur and tibia were removed and decalcified. Bone tissue was
embedded in paraffin, sectioned at 5 µm thickness, and stained with hematoxylin and eosin
(H&E). Brightfield images of the H&E stained slides were acquired using the NanoZoomer
Digital Pathology System (NanoZoomer 2.0-HT, Hamamatsu, Japan).

4.3.5 Data analysis
Image analysis was performed using in-house routines developed on MATLAB R2014b
(Mathworks, MA, USA). ROIs for the femur, tibia, and muscle volumes were drawn on each
slice of T1-weighted, non-CE and CE images using ImageJ (National Institutes of Health, MD,
USA). To minimize variability in inter-scan T1-weighted image intensity resulting from
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unavoidable modest variability in coil placement and subject positioning, CE T1-weighted
images were normalized by the mean voxel intensity of the muscle volume of interest (VOI). T2
parametric maps were generated using non-linear least squares fitting of the equation 𝑆(𝑡) =
𝐴 + 𝐵 × exp(−𝑡/𝐶) for each voxel, where S(t) is the signal intensity, t is TE, A and B are scaling
constants, and C is the voxel-specific T2. The constant, A, accounts for both the positive, nonzero mean of Rician noise and any steady-state, non-zero transverse magnetization resulting
from imperfect, slice-selective 180o refocusing pulses.
The T1-weighted CE 3D images were also analyzed using texture statistics to assess
the spatial distribution of the signal within the femur and tibia VOIs. Image histograms were
distributed into equally sized integer bins and voxels were relabeled to the integer values of their
respective bins. A gray-level co-occurrence matrix (GLCM) was computed on the VOI covering
each neighboring voxel in 3D space. Texture statistics were calculated from the 3D GLCM
(12,13).
Bone histology images were imported into MATLAB using ImageJ and the Bio-Formats
application interface (14). Images were first manually segmented into femur and tibia BM ROIs,
and then into tumor and non-tumor ROIs. Tumor burden (%) was calculated for tumor-bearing
groups as (Total ROI area – Non-tumor area)/(Total ROI area) * 100%.

4.3.6 Statistical analysis
Statistical analysis on histogram and texture statistics from the imaging and histology
was performed using GraphPad Prism 7.0 (GraphPad, CA, USA). One-way analysis of variance
(ANOVA) with Tukey multiple comparisons test was used to assess statistical significance
between multiple treatment groups for femur and tibia VOI individually. A p-value less than 0.05
was defined as statistically significant.
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4.4

Results

4.4.1 Observed differences in normalized 3D CE T1-weighted MRI

Figure 4.2: Representative sagittal sections of T1-weighted CE-MRI. Each voxel in the volume
was normalized by the mean of representative muscle VOI located in the lower leg. (A) Nontumor bearing. (B) Untreated tumor-bearing, week 4. (C) Treated tumor-bearing, week 6. Red
arrows highlight regions of significant spatial intensity variation. Scale bar, 4 mm.
Diffuse tumor burden in the femur and tibia VOIs in treated and untreated
C57Bl/KaLwRij mice bearing intramedullary 5TGM1 tumors was visualized using normalized CE
T1-weighted imaging. Due to heterogeneity in the BM composition of the femur and tibia, endstage untreated mice displayed spatial variation in T1-weighted CE image intensity in the femur,
and to a lesser extent, tibia (Figure 4.2B). By contrast, non-tumor bearing (Figure 4.2A) and
end-stage treated (Figure 4.2C) groups showed minimal spatial heterogeneity in either femur or
tibia. These observations were supported by the equivalent gray-level normalized images, which
corroborated the overall homogeneity of the signal in the non-tumor and treated mice (Figure
4.3A, C) relative to the untreated animals (Figure 4.3B). Mid-stage, untreated (week 3) and
treated (week 4) mice had similar spatial distributions in both femur and tibia (Figure 4.4A-D).
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Textural analysis of these images using 3D GLCM and Haralick features confirmed the
observed spatial distributions. The GLCM autocorrelation, which measures the fineness of the
textured image, was significantly reduced in the femurs of untreated tumor-bearing mice
(p<0.05) relative to the non-tumor bearing and treated tumor-bearing groups (Figure 4.5A).
Furthermore, there was a statistically significant increase in the difference in autocorrelation
between the treatment time points and the pre-treatment baseline relative to the untreated
groups (p<0.01) ((Figure 4.5B). These results demonstrate that region-specific permeability and
contrast agent uptake via vascular availability are affected by bortezomib treatment response.

Figure 4.3: Gray-level, normalized, CE T1-weighted representative sagittal sections. Images
were normalized by distributing the grayscale intensity value of each voxel into 8 equal-width
bins. (A) Non-tumor bearing. (B) Untreated tumor-bearing, week 4. (C) Treated tumor-bearing,
week 6. Scale bar, 4 mm.
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Figure 4.4: Representative sagittal sections of T1-weighted CE and T2 parametric images of
mid-series time points in untreated and treated tumor-bearing mice. (A-B) T1-weighted CE 3D
MRI, normalized by the mean voxel intensity of the representative muscle ROI in untreated
(week 3) and treated (week 4) tumor-bearing. (C-D) T1-weighted CE 3D MRI, normalized by
gray level equalization. (E-F) T2 parametric maps of femur and tibia ROIs overlaid on T1weighted non-CE oblique slices. Scale bar, 4 mm; T2 range, 0-60 ms.
Statistical analysis of mean T1-weighted CE normalized intensities supported the spatial
heterogeneity observations in representative sections (Figure 4.6A). End-stage (weeks 5-6),
treated tumor-bearing mice showed a statistically significant increase in T1-weighted intensity
relative to the mid-stage (weeks 3-4) treated and untreated groups in the tibia (p<0.01).
Interestingly, in the femur, the mean T1-weighted intensity in the non-tumor bearing group was
significantly higher (p<0.001) than in the rest of the groups and had a tighter intra-group
distribution relative to the non-tumor tibia VOI. To minimize the underlying intra-animal
heterogeneity, the %difference between the pre-treatment and the latter stage time-points was
calculated. The end-stage treated group showed a statistically significant increase in the
%difference in T1-weighted intensity relative to the mid-stage treated and untreated groups in
the tibia (p<0.05), but not the femur (Figure 4.6B).
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Figure 4.5: Mean autocorrelation of 3D gray-level co-occurrence matrix (GLCM) in tibia and
femur VOIs in T1-weighted CE images. (A) Mean GLCM autocorrelation for non-tumor bearing
(NT), untreated tumor-bearing at weeks 3 (U3) and 4 (U4), and treated tumor-bearing at weeks
3-4 (MT) and weeks 5-6 (ET) groups. (B) Mean GLCM autocorrelation relative to week 2
baseline for each animal (%difference = (Time-point Mean – Baseline Mean)/(Baseline Mean)).
Statistical significance was assessed using a one-way ANOVA with Tukey multiple comparisons
test performed individually on the tibia and femur VOIs (*p < 0.05). Whiskers indicate 5-95%
confidence intervals.

Figure 4.6: Mean CE T1-weighted intensity, normalized by mean muscle intensity, in femur and
tibia VOIs. (A) Mean CE T1-weighted normalized intensity in non-tumor bearing (NT) mice,
untreated tumor bearing mice at weeks 3 (U3) and 4 (U4), and treated tumor-bearing mice at
weeks 3-4 (MT) and 5-6 (ET). (B) Mean CE, T1-weighted normalized intensity relative to week 2
baseline for each animal (%difference = (Time-point Mean – Baseline Mean)/(Baseline Mean)).
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Statistical significance was calculated using a one-way ANOVA with the Tukey multiple
comparisons test performed individually on the tibia and femur VOIs (*p < 0.05, **p < 0.01, ***p
< 0.001; closed line indicates comparison between two groups, open-ended line indicates
statistical significance between one group against all other included groups). Whiskers indicate
5-95% confidence intervals.

4.4.2 Effect of disease stage and bortezomib therapy on T2 parametric maps

Figure 4.7: Representative T2 parametric maps of femur and tibia BM. (A) Non-tumor bearing
mice. (B) Untreated tumor-bearing mice, week 4. (C) Treated tumor-bearing mice, week 6.
Femur and tibia T2 maps were overlaid on non-CE, oblique, T1-weighted intensity images
normalized by the mean voxel intensity of the muscle ROI. Scale bar, 4 mm; T2 range 0-60 ms.
To identify the effect of treatment on viable tumor burden, T2 parametric maps were
generated. These maps identified substantive changes in the tibia VOI after tumor implantation.
The non-tumor-bearing tibia had low overall T2 (Figure 4.7A), relative to all other groups. By
contrast, representative end-stage untreated (week 4) and treated (week 6) groups displayed
similar overall distribution of T2 values in both VOIs. There was an increase in spatial
heterogeneity in the treated tibia VOI relative to the femur VOI and both VOIs in the
representative untreated image (Figure 4.7B, C). Interestingly, high T2 values (>45 ms) in both
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groups were clustered near the epiphyseal plate of the femur and tibia. This result was seen in
the mid-stage untreated (week 3) and treated (week 4) representative images as well, albeit to a
lesser degree (Figure 4.4E, F). The representative T2 parametric maps correlated with changes
in the viable tumor burden and changes in the homogeneity of the BM tissue observed in the
representative T1-weighted CE images.

Figure 4.8: Mean T2 in femur and tibia VOIs. (A) Mean T2 in non-tumor bearing (NT) mice,
untreated tumor-bearing mice at weeks 3 (U3) and 4 (U4), and treated tumor-bearing mice at
weeks 3-4 (MT) and weeks 5-6 (ET). (B) Mean T2 relative to week 2 baseline for each animal
(%difference = (Time-point Mean – Baseline Mean)/(Baseline Mean)). Statistical significance
was assessed using a one-way ANOVA with Tukey multiple comparisons test performed
individually on the tibia and femur VOIs (*p < 0.05, **p < 0.01, ***p < 0.001; closed line indicates
comparison between two groups, open-ended line indicates statistical significance between one
group against all other included groups). Whiskers indicate 5-95% confidence intervals.
Quantitative analysis of the T2 parametric images showed similar overall trends to the
qualitative observations from the representative parametric images (Figure 4.8A). In both femur
and tibia, mean T2 times in the end-stage (weeks 5-6), treated tumor-bearing group was
significantly increased relative to the T2 times in the mid-stage treated group (p<0.01). The T2
relaxation time in the end-stage, treated group showed a statistically significant increase relative
to the end-stage untreated group in the tibia (p<0.05), but not femur. In both VOIs, the nontumor bearing group had low mean T2, although as observed, the non-tumor T2 in the tibia was
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significantly lower than in the other groups (p<0.001). Following normalization with pretreatment imaging, the treated end-stage and mid-stage groups were more heterogeneous in
the tibia VOI than in the femur (Figure 4.8B). In the tibia, there was a statistically significant
difference in the %T2 difference between the untreated groups and the end-stage treated group
(p<0.01). By contrast, in the femur, there was a significant reduction in the %T2 difference midstage treated relative to the end-stage untreated and treated groups (p<0.05). These results
suggest that the T2 parametric maps are responsive to the overall disease stage following
treatment.
The spatial and temporal distributions of contrast uptake and T2 relaxation times in the
BM were most affected by response to bortezomib therapy. Spatial intensity heterogeneity was
maximized in the untreated tumor-bearing group and reduced following treatment with
bortezomib. Similarly, mean T2 relaxation times were significantly increased following tumor
implantation and showed significant difference from the untreated groups relative to pretreatment imaging. In summary, T1-weighted CE imaging and T2 parametric maps were
indicative of viable tumor burden, with significant longitudinal changes seen at the end-stage of
the treated tumor-bearing group.

4.4.3 Validation of imaging results with H&E of femur and tibia BM
To validate MRI results, the femur and tibia were extracted at end-stage disease and
stained with H&E. The %tumor burden was quantified as the total tumor tissue relative to nontumor tissue in the femur and tibia ROIs. Non-tumor bearing mice had high lipid content
clustered near the femur epiphyseal plate and low overall cell density (Figure 4.9A). In the endstage, untreated tumor-bearing group, the healthy BM was overtaken by densely packed,
mononuclear tumor cells (Figure 4.9B, Figure 4.10B). Non-tumor BM tissue was sequestered
in the epiphysis of the femur and tibia. By contrast, the end-stage, treated tumor-bearing group
showed a statistically significant reduction in tumor burden in the femur (p<0.001) and tibia
(p<0.001) relative to the untreated mice (Figure 4.9C, Figure 4.10B). Tumor tissue was
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primarily concentrated proximal to the epiphyseal plate in both femur and tibia, with minimal
tumor burden at distal sites in either bone (Figure 4.9C). Tumor burden was also highest near
the epiphyseal plate in the mid-treatment cohort, although the overall distribution of tumor
burden within the cohort was highly heterogeneous in both femur and tibia (Figure 4.10A, B).
These results suggest that bortezomib therapy restricts tumor cell growth to the rapidly growing
epiphyseal plate region, which may correlate with the observed high T2 values near the
epiphyseal plate in the end-stage treated group (Figure 4.8C).

Figure 4.9: Representative H&E sections. (A) Non-tumor bearing mice. (B) Untreated tumorbearing mice, week 4. (C) Treated tumor-bearing mice, week 6. Green outline indicates tumor
boundaries. Top inset highlights non-tumor cells, as indicated by the presence of
megakaryocytes (red arrowhead) and segmented nuclei (red arrow). The bottom inset highlights
tumor cells, as indicated by the presence of mitoses (green arrowhead) and oval plasma cell
nuclei (green arrow). Scale bar, 500 µm; inset scale bar, 20 µm.
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Figure 4.10: Representative H&E sections and quantification of total tumor burden. (A) Midtreatment, week 4. Green outline indicates tumor boundaries. Top inset highlights non-tumor
cells, as indicated by the presence of segmented nuclei (red arrows). Bottom inset highlights
tumor cells, as indicated by the presence of mitoses (green arrowheads) and oval plasma cell
nuclei (green arrows). (B) %Tumor burden in untreated week 4 (U4) and treated weeks 3-4 (MT)
and weeks 5-6 (ET) (%tumor burden = (Total Tissue Area – Non-tumor Area)/(Total Tissue
Area)*100%). Statistical significance was assessed using one-way ANOVA with Tukey multiple
comparisons test on the tibia and femur individually (***p<0.001). Whiskers denote 5-95%
confidence intervals. Scale bar, 500 µm; Inset scale bar, 20 µm.
In summary, histology and ex vivo tumor burden quantification demonstrated the
difference in the distribution of tumor between the end-stage untreated and treated tumorbearing groups. BM in the femur and tibia of untreated animals was dominated completely by
tumor tissue, while tumor burden was concentrated proximal to the epiphyseal plate in the
treated animals. Tumor cell density was also reduced in both tibia and femur, especially at the
end-stage, following relapse from bortezomib therapy. Spatial distributions of the tumor and
normal BM in the tibia and femur were similar to the observed trends in the imaging acquired
using T1-weighted CE and T2 parametric pulse sequences.
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4.5

Discussion
This study marks one of the first instances utilizing multi-parametric MRI to longitudinally

follow changes in the BM in response to MM stage and therapy in a preclinical
immunocompetent model. Previously, Fryer et al demonstrated that a combination of in vivo
bioluminescence and T2-weighted tumor volume were correlated to therapy response in an
intratibial immunocompromised model of MM (15). Similarly, Gauvain et al used a metastatic
melanoma model in immunocompetent C57Bl/6 mice to identify early stage bone metastases
using a combination of T2-weighted and T2 parametric imaging (16). In both studies, the tumor
model resulted in focal lesions, which have well-defined boundaries. However, in this study, a
diffuse intramedullary tumor model was generated by intravenous injection of syngeneic tumor
cells within an immunocompetent strain. The advantages of this model include the preservation
of the immune response to the myeloma cells and the presence of therapy-induced
inflammation. Since MRI offers high soft-tissue contrast and spatial resolution, we hypothesized
that MRI could provide a noninvasive, longitudinal approach for studying changes in the BM
induced by bortezomib therapy and MM disease progression. The key MR features and their
corresponding biological correlates in the BM are summarized in Table 4.1.
Table 4.1: Summary of MR markers and their corresponding biological features for each
imaging group relative to the untreated week 4 group. 0, no effect; +, difference in features; ++,
significant difference in features.
Untreated
MR marker
Autocorrelation
(femur)
Mean normalized T1weighted intensity
Mean T2 relaxation
times
H&E cell density

Biological
Correlate
Tissue
Homogeneity
Viable tumor
burden
Diffuse tumor
burden
Total tumor
burden

Treated

Non-tumor

Week
3

Week
4

Mid-stage
(Wks 3-4)

Relapse
(Wks 5-6)

++

0

0

+

++

N/A

0

0

++

++

N/A

0

0

+

++

N/A

N/A

0

++

++
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T1-weighted, CE, 3D MRI signal intensities were indicative of contrast uptake within
regions of tissue. Gadolinium-based contrast agents induce shortening of T1 relaxation times,
resulting in increases in T1-weighted signal intensity in highly vascular and permeable regions
relative to necrotic and less vascularized regions (17). The uptake of contrast within the BM in
the femur and tibia was spatially heterogeneous, especially in the end-stage, untreated, tumorbearing animals. In general, significant spatial heterogeneity and the presence of well-defined
regions of differential contrast uptake within the BM were restricted to the femur in the untreated
mice. This could be due to the presence of higher overall hematopoiesis in the femur, with
concentrated marrow adipocyte tissue near the epiphyseal plate in the femur. The role of
adipose tissue in myeloma progression is considered controversial, with some literature
presenting a supporting role for adipose tissue and other studies showing that adipose tissue
may restrict myeloma growth (18). Nevertheless, the presence of adipose tissue in the BM may
result in increased myeloma cell viability, thus generating the region-specific uptake patterns
seen in the T1-weighted CE MRI. The underlying hematopoietic niches may also drive the
concentrations of vascularized and accessible tumor burden within the femur BM, especially in
sites distal to the femur epiphyseal plate.
Treatment with bortezomib also induced increases in contrast agent uptake within the
BM in both femur and tibia. Bortezomib causes significant marrow remodeling, resulting in
reduction in osteoclast activity and cytokine secretion, and inhibition of tumor-induced
angiogenesis (19,20). At the same time, healing and tumor cell death induced by bortezomib
may also generate increases in angiogenesis and inflammation, which may result in increased
uptake of contrast within high tumor burden regions after relapse. By contrast, in the mid-stage
treated group, bortezomib efficacy and inhibition of neo-vascularization likely dominates,
resulting in low normalized T1-weighted intensity.
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In contrast to T1-weighted CE imaging, which was directly correlated to tumor
vascularization and permeability, T2 parametric maps are representative of tumor burden and
overall water content. There was less spatial heterogeneity in the T2 parametric maps, although
this observation may have partially resulted from the reduced resolution in the T2 maps
compared to the T1-weighted 3D images. T2 values were highest in both treated and untreated
mice near the epiphyseal plate. This may be caused by the high tumor burden in those regions
due to the presence of hematopoietic niches in the epiphysis and the availability of tumorpromoting cellular and extracellular matrix factors. Interestingly, mean T2 relaxation time was
significantly increased in the tibia of the tumor-bearing groups relative to the non-tumor bearing
group. The increase in T2 relaxation from the non-tumor group compared to the tumor-bearing
groups was not as exaggerated in the femur. These trends may be a function of the underlying
composition of the femur and tibia in the C57Bl/KaLwRij model. There is higher hematopoietic
and cellular content in the femur BM, with the tibial BM, especially in the distal tibia, dominated
by adipose tissue (21). In the presence of myeloma, T2 relaxation times increased, although
interestingly, the relative difference in T2 relaxation was higher in the treated animals than in the
untreated groups. These results suggest that T2 relaxation is indicative of overall tumor burden
and post-treatment disease progression.
Histology with H&E staining was used to validate the MRI observations. Tumor burden in
the end-stage untreated animals completely displaced normal BM in the femur and tibia. This
result approximates advanced MM in humans, with homogeneous, packed diffuse infiltration
dominating the BM (22). The lack of marrow adipose tissue in the tumor-bearing animals may
be partly due to the age of the mice, since significant changes in marrow adipocyte depositions
occur in older animals. The study used young, 4-6 week old mice, since young animals have
high rates of bone remodeling and higher plasticity in the marrow composition. Both midtreatment and relapsed end-stage cohorts had reduced tumor burden, which was concentrated
proximal to the epiphyseal plate. However, cells in the BM of the mid-treatment group were
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more densely packed compared to the relapsed group, and were qualitatively similar in density
to the end-stage untreated cohort. The observed continuum of cell densities in the treated and
untreated groups, and the highly heterogeneous tumor burden in the mid-treatment group, is
likely caused by the individual kinetics and response rates to bortezomib therapy. The
concentration of the tumor tissue at the epiphyseal plate also agreed with the observed
increases in normalized T1-weighted intensity and T2 relaxation times at the epiphyseal plate.
The tumor cells were also less densely packed in the treated mice relative to the highly packed
tumor tissue in the untreated BM, which likely resulted in improved viability. It is likely that the
improvement in tumor viability resulted in the relatively large difference in T2 relaxation time
following therapy.
The main limitations of this study are the absence of validation with a focal lesion model
a non-tumor bearing, treated control cohort. Contrast uptake and changes in the spatial
distribution of signal intensities were affected by the underlying heterogeneity in the distribution
of hematopoietic and fatty marrow in the BM. Comparison with a well-circumscribed, focal lesion
model may further validate the observations of this study and minimize the effect of
spatiotemporal heterogeneity on the imaging results, especially at early and mid-stage disease.
Finally, T2 relaxation times and normalized T1-weighted intensities in the both tumor-bearing
groups were compared to the non-tumor bearing, untreated cohort. Since mean T2 relaxation
times were significantly increased from the non-tumor group to the tumor bearing groups, an
additional cohort with non-tumor bearing, bortezomib-treated animals may provide a useful
control for therapy-induced inflammation.

4.6

Conclusion
In conclusion, this study demonstrates that T1-weighted CE MRI and T2 relaxation times

are indicative of disease progression and response to bortezomib therapy in an
immunocompetent intramedullary model of MM. As such, it marks the first instance of using MRI
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to longitudinally study the behavior of the BM in the preclinical model with diffuse MM infiltration,
showing significant histogram and textural feature correlation to viable tumor burden in the
presence of myeloma therapy. The study also highlighted potential preclinical MRI markers for
assessing changes to the BM induced by MM and therapy. Future studies will include MR
spectroscopy to assess changes in adipose tissue composition in response to myeloma in both
young and old mice, the use of alternate hypo-proliferative myeloma cell lines, and testing with
combination therapies and newer proteasome inhibitors.
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Chapter 5: Conclusions and Future Work
5.1

Summary
This thesis aimed to identify preclinical imaging markers correlating to therapy response

in MM for efficient imaging, with the long term goal of improving staging and patient
stratification. To achieve this goal, the project was designed to address myeloma pathogenesis
and therapy efficacy through a micro-environmental lens at different levels of granularity. Thus,
these studies followed myeloma progression and response to clinically relevant therapies
through three specific aims:
Aim 1: To validate LAT1 surface expression imaging using FDOPA-PET and develop FDOPAPET uptake metrics as a surrogate for melphalan efficacy
In this study, I adapted the phenylalanine analog 18F-FDOPA for imaging melphalan
therapy response in extramedullary myeloma. The uptake of melphalan and 18F-FDOPA is
mediated by LAT1, which is overexpressed in several cancers and is linked to poor prognosis in
MM. 18F-FDOPA uptake was significantly reduced in melphalan-treated mice, as was uptake of
the gold standard 18F-FDG. These results demonstrated that 18F-FDOPA-PET provides
complementary imaging of LAT1 behavior in MM to currently established 18F-FDG-PET.
The conclusions regarding 18F-FDOPA and 18F-FDG were validated using
immunohistochemistry of the tumor and muscle tissue using antibodies against LAT1, GLUT1,
and CD31. GLUT1 and CD31 are markers for glucose uptake and vascularity, respectively.
LAT1 expression in melphalan-treated tumors was heterogeneous, and was increased relative
to vehicle-treated tumors in some animals, while GLUT1 expression remained qualitatively
similar between the treated and untreated cohorts. This heterogeneity in LAT1 expression is
likely driven by an increase in tissue vascularity, as visualized by anti-CD31 staining, and
reduction in structural tumor volume. These results highlight the importance of LAT1 for
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myeloma cell function, and imply the presence of other sources of resistance to offset the
melphalan-induced downregulation of LAT1 expression.
Aim 2: To study the uptake of the VLA-4 specific optical contrast agent for identifying VLA-4
expression in vivo and in response to bortezomib therapy
In this aim, I comprehensively validated the peptidomimetic near-infrared fluorophore
LLP2A-PEG4-Cy5 (LLP2A-Cy5) for economical and high-throughput imaging of activated VLA-4
expression. The Shokeen research group has extensively published on the use of the nuclear
LLP2A analog for imaging activated VLA-4 expression in intramedullary myeloma pathogenesis.
Furthermore, we have shown cell line and patient-specific heterogeneity in VLA-4 expression
using the fluorescent LLP2A-Cy5. Here, we were interested in imaging VLA-4 expression
following bortezomib therapy, since bortezomib induces downregulation of VLA-4 and causes
partial inhibition of cell adhesion-mediated drug resistance. Imaging was performed in
intramedullary, diffuse lesions, within an immunocompetent MM model to accurately study
effects of the immune system on MM pathogenesis.
The results of this aim proved the sensitivity and specificity of LLP2A-Cy5 relative to the
more established nuclear LLP2A conjugate. In vitro studies showed nanomolar specificity of
LLP2A-Cy5 to activated VLA-4 expression, while confocal imaging established the
predominantly cell surface concentration of LLP2A-Cy5 binding. Ex vivo analysis of LLP2A-Cy5
uptake demonstrated the viability of using activated VLA-4 expression for studying the effects of
proteasome inhibitor therapy in MM.
Aim 3: To identify preclinical MRI parameters for longitudinal imaging of diffuse, intramedullary
tumor burden in response to myeloma therapy
Finally, in aim 3, I addressed the gross, anatomical scale changes in the BM induced by
both MM disease progression and response to bortezomib therapy. Bortezomib induces BM
remodeling in addition to abrogating adhesion-mediated drug assistance. To assess BM
remodeling in a longitudinal manner in a diffuse infiltrative intramedullary MM model, I evaluated
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preclinical, high-resolution MRI parameters. While MRI is used extensively in MM clinical care,
there is a scarcity of preclinical MRI studies for noninvasive, longitudinal imaging of MM
pathogenesis. In this study, MR T1-weighted and T2 parametric markers were correlated to
structural changes in the BM following bortezomib therapy.
The MR imaging results were validated with histology of the femur and tibia BM at each
treatment stage. H&E staining of the BM was used to assess tumor burden. In untreated
animals, end-stage disease caused near-complete infiltration of the BM space by myeloma
cells, while in end-stage, treated disease, the tumor was primarily concentrated near the
epiphyseal plate in the distal femur and proximal tibia. These observations correlated to T1weighted contrast uptake and parametric T2 using both summary statistics and spatial analysis.
Crucially, high-resolution imaging established the spatial heterogeneity between BM sites.

5.2

Limitations
There are certain limitations to our approach in this project. Most aim-specific limitations

are addressed in each chapter individually, but there were some inherent, general limitations
that may affect the results in the project. The primary limitations were the use of a single
myeloma cell line and sample sizes in some of the experiments. Both limitations are easily
addressed by additional validation studies.
Additionally, in aim 1, the use of the 5TGM1-GFP cell line presented translatability
challenges, due to two main factors. The cell line is highly proliferative, resulting in rapidly
growing tumors, which do not necessarily represent the general MM progression, where the
medullar spaces motivate quiescence and slow growth. As a result of this growth behavior,
5TGM1 cells are also highly glucose avid, which increases 18F-FDG intratumoral uptake. In the
general MM population, the overexpression of GLUT1 and hexokinase is inconsistent, resulting
in poor 18F-FDG sensitivity in intramedullary disease. These concerns were slightly abrogated
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due to the use of a late-stage, extramedullary model, although it may be necessary to study
intramedullary models to establish 18F-FDOPA-PET for use in MM care.
In aims 1 and 2, single time point imaging was used, at the end-stage of the treated and
untreated groups. This was done to reduce complexity inherent in longitudinal imaging.
However, due to clonal and spatiotemporal heterogeneity in intra- and inter- patient levels, the
comparison of these two groups may lose relevant information regarding changes in expression
resulting from disease progression. Use of longitudinal imaging would be especially helpful for
aim 2, where end-point imaging of the LLP2A-Cy5 contrast reduces the value of fluorescent
imaging.
In aim 3, the intra-site heterogeneity was hinted at, but not fully studied. Imaging of the
femur and tibia BM showed regional differences in viable tumor burden and BM recovery
following bortezomib therapy. In clinical MM care, MRI of the spinal column and vertebrae is
combined with the leg bone imaging. Furthermore, in patients, the distal BM is primarily
composed of adipose marrow, with hematopoietic marrow concentrated in spinal and pelvic
sites. Our model did not approximate this behavior, since we used young, 6-8 week old mice.
These mice were used due to their rapid bone turnover and corresponding BM activity, which
exaggerated the myeloma-induced changes in the BM for MR validation.
Finally, we used single agent therapies for each of our aims to simplify the experimental
models and validate the imaging strategies. Single agent treatment is not used in clinical care to
delay the onset of resistance to the individual agents. Future studies should address this
limitation by using clinically relevant combinations to study the effect on the targeted imaging
biomarkers for increasing the translatability and clinical value of the imaging strategies tested in
this thesis.

109

5.3

Future work
As with the limitations, aim-specific future studies were addressed in each chapter. Here,

briefly, there are some general future studies that could be performed to improve upon the
results and conclusions generated by each aim.
One important addition to the intramedullary model would be to test intramedullary
imaging on focal lesions, since MM patients typically have a combination of diffuse and focal BM
lesions. Such a model would be generated using direct injection of cells into the tibia. Crucially,
this approach also generates metastatic tumor burden at late stages of the disease, and may
also show diffuse infiltration in the spinal column. Use of multiple cell lines can also approximate
different MM pathogenic behaviors for assessing the robustness of each biomarker in the
presence of heterogeneous protein expression and growth profiles.
This thesis highlighted use of longitudinal imaging for identifying changes in the BM
microenvironment in response to disease progression and treatment response. The use of the
5TGM1 cell line also allowed the influence of the intact immune system on the myeloma
pathogenesis, although due to the rapid proliferation profile in vitro and in vivo, disease
progression within the BM was accelerated. In addition, the cell line presented an external
stressor, which may have adversely affected the biology, resulting in potentially inaccurate
conclusions drawn from the imaging data. As a result, one exciting strategy for studying
changes in biomarker expression and BM remodeling is to use naturally progressing MM model
with the vk*myc animal model. Longitudinal imaging in this model would help identify novel
features that could be directly translated for clinical care.
Finally, there is growing availability of tandem PET and MRI systems (PET/MRI) that aim
to utilize the functional imaging and high-resolution, soft tissue contrast of the constituting
technologies. Our work has highlighted the use of each technology in assessing changes to
expression of critical surface markers and the overall BM structure. Therefore, there is potential

110

for using PET/MRI to generate co-registered results that can be used for early stratification of
therapy response.

5.4

Conclusions
In conclusion, this study used a combination of qualitative observations and quantitative

metrics for addressing therapy response monitoring and stratification in MM. We took an
integrated, multi-modal approach to assessing therapy response by observing changes to a
spectrum of myeloma pathogenic behaviors. This structured approach harnessed the unique
role of the BM microenvironment in supporting MM progression and response to clinical relevant
therapies. In doing so, we have validated the use of several imaging markers in preclinical MM
models that have translation potential.
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